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Valley fever virus (RVFV), an RNA virus that causes disease in humans and animals, and the secreted
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diarrheal disease. In 2015, the WHO named the ten emerging diseases most likely to cause severe
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strategy of forward genetic screening in a mutagenized human haploid cell library. Our RVFV screen
identified a suite of enzymes involved in glycosaminoglycan biogenesis and transport, including several
components of the cis-oligomeric Golgi (COG) complex. In addition, we identified the gene PTAR1,
disruption of which led to RVFV resistance and reduced heparan sulfate surface levels. Biochemical and
genetic approaches were utilized to show that both pathogenic and attenuated RVFV strains require GAGs
for efficient infection in some cell types, with the block to infection being at the level of virion attachment.
Our TcdB screen identified the Wiskott–Aldrich syndrome protein and SCAR homologue (WASH) complex
as a host cellular factor supporting TcdB intoxication. Involvement of the WASH complex in TcdB entry
was validated by pharmacologic inhibition of recycling endosomes and the use of mouse fibroblasts
lacking a functional WASH complex due to genetic ablation of the core WASH1 gene. The host factors
supporting TcdB internalization and transport are largely unknown, and our data help to elucidate the
mechanism of intoxication of this important and poorly-characterized virulence factor.
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ABSTRACT
FORWARD GENETIC SCREENING IN HUMAN HAPLOID CELLS
TO IDENTIFY HOST FACTORS REQUIRED FOR VIRUS AND TOXIN ENTRY
Amber M. Riblett
Dr. Robert W. Doms

My dissertation research has focused on identifying host cellular factors required
by the bunyavirus Rift Valley fever virus (RVFV), an RNA virus that causes disease in
humans and animals, and the secreted Toxin B (TcdB) from Clostridium difficile, a
bacterial pathogen that causes severe antibiotic-associated diarrheal disease. In 2015,
the WHO named the ten emerging diseases most likely to cause severe outbreaks in the
near future, and three are caused by bunyaviruses (including RVFV).

Concern is

likewise mounting about the increasing incidence, virulence, and antibiotic-resistance of
C. difficile infection worldwide. A better understanding of the molecular details of the
pathogenesis of these diseases is urgently needed in order to inform the development
and application of therapeutic interventions.

The data presented in this thesis

summarize the results of two independent screening projects, each utilizing a strategy of
forward genetic screening in a mutagenized human haploid cell library.

Our RVFV

screen identified a suite of enzymes involved in glycosaminoglycan biogenesis and
transport, including several components of the cis-oligomeric Golgi (COG) complex. In
addition, we identified the gene PTAR1, disruption of which led to RVFV resistance and
reduced heparan sulfate surface levels.

Biochemical and genetic approaches were

utilized to show that both pathogenic and attenuated RVFV strains require GAGs for
efficient infection in some cell types, with the block to infection being at the level of virion
iv

attachment.

Our TcdB screen identified the Wiskott–Aldrich syndrome protein and

SCAR homologue (WASH) complex as a host cellular factor supporting TcdB
intoxication.

Involvement of the WASH complex in TcdB entry was validated by

pharmacologic inhibition of recycling endosomes and the use of mouse fibroblasts
lacking a functional WASH complex due to genetic ablation of the core WASH1 gene.
The host factors supporting TcdB internalization and transport are largely unknown, and
our data help to elucidate the mechanism of intoxication of this important and poorlycharacterized virulence factor.
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CHAPTER 1: INTRODUCTION

INVESTIGATING HOST-PATHOGEN INTERACTIONS
Our bodies are constantly assailed by disease-causing microorganisms wielding
a diverse arsenal of molecular weapons that they employ to gain entry into our tissues,
break down our defenses, and reprogram our cellular machinery. The foot soldiers
carrying out these attacks - such as viruses, bacteria, and their secreted toxins - rely on
a large number of host cellular factors and pathways as they enter, traffic through, and
exert various pathophysiological effects upon the host cell. From the initial interactions
between the pathogen’s surface proteins and the host cell’s plasma membrane to the
apoptosis, lysis, or takeover of the host cell, a pathogen uses its limited protein reservoir
to co-opt the much more extensive machinery found within the host. A virus can use this
cellular infrastructure to carry out its genome replication, assemble new virions, and
move throughout the host cell. Bacterial toxins hitchhike along host endocytic pathways,
rely on host cell proteases for cleavage, and trigger signaling cascades to modify host
cell function in a way that benefits the bacteria. This manipulation of the resources
offered by the host with which it has coevolved is a defining trait of our microscopic
invaders, and identification of those host factors upon which the pathogen relies (such
as cell surface receptors) has provided invaluable information about the lifecycles and
mechanisms of action of the causative agents of many important human diseases.
Traditionally, relatively reductionist approaches have been taken to identify
specific interactions between pathogen and host cell molecules. More recently, rapid
advances in high-throughput screening technologies based upon small molecules, loss1

of-function libraries, and interactome characterization have informed our understanding
of nearly every stage of host-pathogen interaction and identified targets for therapeutic
intervention. The study of how pathogens co-opt cellular machinery has also yielded
tremendous insight into the function of human biological pathways, such as the
discovery of RNA splicing in adenovirus-infected cells that led to the subsequent
understanding of this as a normal cellular function (1, 2). I was extremely interested in
the power of high-throughput screening techniques to identify novel aspects of pathogen
entry and infection, and also in the ability of such studies to teach us about fundamental
cell biology.

Of particular interest to me was the application of these screens to

emerging and poorly-characterized diseases. My dissertation research has therefore
focused on optimizing a forward genetic screening strategy to identify host cellular
factors that are required by bunyaviruses, a family of RNA viruses that can cause
disease in humans and animals, and the secreted Toxin B from Clostridium difficile, a
bacterial pathogen that causes a severe antibiotic-associated diarrheal disease in
humans.
VIRAL INFECTION OF HOST CELLS
Viruses that cause human disease package their DNA or RNA genomes into
nucleocapsid complexes that are sometimes surrounded by a lipid bilayer membrane
called the viral envelope. Structural proteins known as the viral glycoproteins stud the
membranes of these enveloped viruses and are available to access and interact with the
surface of the host cell. A myriad of other proteins, such as viral RNA-dependent RNA
polymerases, reverse transcriptases, and matrix proteins may or may not be present
inside of the virion, depending on the type of virus.
2

During the first step of virus entry, one or more viral proteins that are exposed
(glycoproteins in the case of enveloped viruses) interact with attachment factors and
receptors on the host cell surface. There is a tremendous diversity of both the type of
host factors used by the virus during this stage of entry as well as the nature of the
interactions that occur.

Virions have been shown to interact with proteins,

carbohydrates, and lipids – and these interactions vary greatly in their strength and
duration [reviewed in (3)].

These components at the cell surface may serve as

attachment factors that concentrate the virus particles in two dimensions, such as
heparan sulfate proteoglycans that interact with the E2 glycoprotein of hepatitis C virus
(HCV) during the initial binding of the virus to the cell (4).

They may also induce

conformational changes that allow the virus to directly fuse with the cell membrane.
During entry of human immunodeficiency virus type 1 (HIV-1), for example, its
glycoprotein Env first binds to the CD4 receptor, and this binding induces a
conformational change that allows Env to bind its coreceptor (CCR5 or CXCR4), which
leads to membrane fusion [reviewed in (5)]. Cell surface components may also function
as entry receptors that facilitate uptake of the virus particle into the host cell’s endocytic
pathway, as is the case for GD1a-mediated uptake of polyomavirus into early
endosomes (6-8). The interaction between the virus and cell surface proteins might also
serve to transduce signals that in some way reprogram the cell to make it more
susceptible to infection, such as the actin rearrangement triggered by tyrosine kinase
activation following binding of simian virus 40 (SV40) to its receptor [reviewed in (3)].
To enter the cell, viruses are able to utilize a range of available existing endocytic
pathways.

Pinocytic uptake mechanisms, such as clathrin-mediated endocytosis,

macropinocytosis, and caveolae-mediated endocytosis are the most commonly used,
3

but use of other pathways, such as phagocytosis, has been demonstrated, as well as
variations on each of these pathways, and indication of entry via novel or
uncharacterized pathways. Interestingly, it has also been found that some viruses are
capable of entering host cells via multiple routes, often in a cell-dependent manner. For
example, influenza A virus, which usually enters through clathrin-coated pits, can in
some cases utilize macropinocytosis as an alternative entry pathway (9-11). Following
their endocytosis, virions find themselves in the lumen of a primary endocytic vesicle,
such as an early endosome, macropinosome, or a caveosome. From there, the virus
must penetrate through its vacuole to deliver its genome into the host cell cytosol. For
enveloped viruses, this process involves viral glycoprotein-mediated fusion of viral and
vesicular membranes. Cues from the maturing endosomes, such as a lowering of pH,
trigger conformational changes in the glycoproteins, which are then able to effect fusion
of the membranes.
After gaining access to the cytosol, the virus needs to uncoat its genome in order
to begin the process of replication. For RNA viruses, this typically takes place in the
cytoplasm (often in intimate association with organelle membranes) whereas most DNA
viruses replicate in the nucleus. As a general rule, viral capsids remain intact until they
have trafficked to their site of replication. Viruses that replicate in the nucleus utilize
many different strategies of gaining entry to this organelle.

HSV-1 and adenovirus

nucleocapsids traffic to the nucleus and then dock at the nuclear pore complex (NPC),
where they uncoat and deliver their genomes directly into the nucleus (12-14). Some
other DNA viruses move either fully or partially through the NPC before uncoating their
genome. Regardless of the eventual site of replication, to reach it, the incoming virion
(or trafficking capsid) is reliant upon the transport machinery of the cell. For example,
4

viruses have been shown to depend upon actin and related proteins (including the
Arp2/3 complex and Rho GTPases) or movement along microtubules by dyneins and
kinesins, as well as other accessory proteins that act to coordinate transport, such as
Rab GTPases, tethering complexes, etc. [reviewed in (15)].
At the site of replication, many viruses induce the formation of virus factories,
dramatic rearrangements of organelle-derived membranes that serve to facilitate the
efficient replication of viral genomes and proteins. Membranes for virus factories have
been shown to be derived from lysosomes, smooth and rough ER, the Golgi apparatus,
and even autophagosomes. Virus factories can be formed by enveloped as well as nonenveloped viruses, can be located in many different subcellular locations, and can take a
variety of shapes. For example, adenoviruses and polyomaviruses (both non-enveloped
DNA viruses) set up aggresome-like virus factories in the nucleus, whereas flaviviruses
and coronaviruses (enveloped RNA viruses) generate virus factories that take the shape
of double-membrane vesicles in association with the ER. These virus factories can help
to shield viral components from host cell immune detection, act as a scaffold for
replication complexes, and recruit cellular factors such as mitochondria [reviewed in
(16)].

Once a sufficient number of viral proteins and genome copies have been

generated, they assemble into virions and are released from the infected cell.

For

enveloped viruses, this step involves the theft of host membrane at the site of budding
with the assistance of recruited cellular membrane deformation machinery.

As this

deformation must occur in a “reverse topology,” such that the virion buds away from the
cytoplasm, a number of enveloped viruses have been shown to recruit the host ESCRT
(endosomal sorting complexes required for transport) proteins, the only cellular pathway
yet identified that performs membrane deformation in this direction. The first described
5

and best characterized example of virus hijacking of ESCRT machinery for virion
budding is the recruitment by retroviral Gag polyproteins of ESCRT and associated
proteins to the plasma membrane by means of amino acid sequences that mimic those
used by cellular adaptor proteins (17-20). Some enveloped viruses, such as influenza A
and Semliki Forest virus, have evolved mechanisms of ESCRT-independent membrane
deformation during virion release (21, 22). Viruses that bud intracellularly (for example,
into the Golgi apparatus) must use the host cell’s exocytic machinery to traffic in vesicles
to the plasma membrane to be released. Other viruses spread within the infected host
by means of cell-to-cell transmission, bypassing the need for release of infectious virions
and cell-free dissemination.
Our ability to glean insight into the mechanistic detail of these later stages of
virus replication has been hampered by a lack of assays to detect viral assembly and
release that are amenable to the most commonly used high-throughput screening
techniques. Traditionally, screening for cellular factors that impact virus replication has
employed reporter genes or cytotoxicity as a read-out of viral infection. However, for
most viruses, this places the temporal limit of phenotype detection at the stage of
translation of viral proteins, and does not allow for the detection of meaningful and
interesting defects in assembly or release of virions. For this reason, our understanding
of the entry pathways utilized by many viruses is often more extensive than our
understanding of the details of their assembly and release processes.
THE BUNYAVIRIDAE
Bunyaviruses are enveloped single-stranded negative-sense RNA viruses that
comprise five genera: Phlebovirus, Orthobunyavirus, Nairovirus, Tospovirus, and
6

Hantavirus. Within these genera are more than 350 viruses, making the Bunyaviridae
the largest family of RNA viruses in the world (23).

Most of these viruses infect

arthropods, although some can infect plants or rodents. Of the bunyaviruses that infect
arthropods and rodents, a number can be borne by these vectors into human hosts
where they cause a wide range of diseases.

Notable human pathogens within the

Bunyaviridae family include Crimean Congo Hemorrhagic Fever virus (CCHFV), a
Nairovirus, which is endemic to regions of Africa, Europe, and Asia, and causes a febrile
illness characterized by joint pain and vomiting that can progress to uncontrolled
bleeding (24). The Hantavirus genus includes the causative agents of Hemorrhagic
Fever with Renal Syndrome (HFRS) in Europe and Asia and Hantavirus pulmonary
syndrome (HPS) in the Americas.

The emergence and spread of newly-identified

bunyaviruses, as well as important progress in recent years toward a more detailed
understanding of bunyavirus structure and genetics, has renewed interest in this large
and diverse family of viruses.
The bunyavirus that was the focus of much of my doctoral work is the
phlebovirus Rift Valley fever virus (RVFV), named for the disease that was first
described during an epidemic in 1931 at a sheep farm in the Rift Valley of Kenya (25,
26).

Rift Valley fever is a viral zoonosis that passes into livestock and human

populations via a number of mosquito vector species. In livestock, the disease is fatal to
newborn animals and causes spontaneous abortions in pregnant animals; in humans it
is a febrile illness which progresses, in approximately 8% of patients, to a severe
disease characterized by encephalitis, retinitis, or hemorrhagic syndrome (27).

Rift

Valley fever remained confined to sub-Sahran Africa until 1977, when 18,000 people
became ill during an outbreak in Egypt; in 2000, it spread beyond the African continent
7

into Saudi Arabia and Yemen (28). Because of the broad host tropism of this virus and
the ease with which it moves into the dominant mosquito species in a given region, there
is great concern that climate change will expand the geographical range of its current
vectors, allowing the virus to move into naive populations (29, 30). This is particularly
alarming as recent outbreaks have seen mortality rates increase - an outbreak in 2007 in
Kenya reported a 29% case fatality rate, compared to the historical average of 0.5-1.0%
mortality (28). As there are currently no FDA-approved vaccines or therapeutics, a better
understanding of how the virus that causes Rift Valley fever replicates within its host will
be of great benefit.
BUNYAVIRUS STRUCTURE AND ENTRY
The bunyavirus genome comprises a small (S), medium (M), and large (L)
segment that encode, respectively, the nucleocapsid protein (N), the two glycoproteins
(Gn and Gc), and the viral RNA-dependent RNA polymerase (L). Three nonstructural
proteins are also encoded: two on the M segment, termed NSm1 and NSm2; and one on
the S segment, termed NSs. These nonstructural proteins play important roles during
pathogenesis, such as suppressing apoptosis and limiting the IFN-mediated antiviral
response, but they are dispensable for growth in tissue culture (31). Bunyaviruses have
broad tropism and enter mammalian cells via receptor-mediated endocytosis. Entry of
RVFV into dendritic cells has been shown to be mediated by the C-type lectin Dendritic
Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) but as
this lectin is not expressed on most of the cell types that RVFV productively infects, the
receptor (or receptors) used by the virus to enter other cells remains unidentified (32). It
is also unclear precisely what cellular endocytic machinery is required for RVFV entry. A
8

study using non-replicating RVFV virus-like particles (VLPs) reported that the entry of
these particles into BHK-21 and A549 cells was both dynamin- and clathrin-dependent
(33). The same year, Harmon and colleagues demonstrated that the MP-12 attenuated
vaccine strain of RVFV enters HepG2 and HeLa cells in a caveolae-mediated, clathrinindependent manner (34).

Our lab has shown that MP-12 infection of 293T and

Drosophila S2 cells was blocked by inhibitors of macropinocytosis (35).
Following

endocytosis,

the

bunyavirus

envelope

glycoprotein-driven fusion with the endosomal membrane.

membrane

undergoes

See Figure 1-1 for an

overview of the bunyavirus replication cycle. The Gc glycoprotein of RVFV is a Class II
fusion protein (36), and acidification of the endosomal compartment triggers a
conformational change that exposes hydrophobic residues that insert into the host
membrane and mediate fusion. For RVFV Gc, the pH threshold at which this occurs has
been reported to be around 5.5 - 5.7, which is consistent with fusion from within the late
endosome (33). However, Rab7, which is the Rab GTPase primarily responsible for late
endosomal maturation, is not required for the entry of many bunyaviruses, including the
nairovirus CCHFV (37, 38), the orthobunyavirus La Crosse virus (39), and the
phlebovirus Uukuniemi virus (40).
Once membrane fusion has occurred, the ribonucleoproteins (RNPs), comprising
the three genome segments encapsidated by the nucleocapsid protein N, are released
into the cytoplasm. The viral RNA-dependent RNA polymerase then transcribes viral
mRNAs, and viral proteins are translated in association with ER-derived membranes.
Within the ER, the bunyavirus Gc and Gn proteins form heterodimers after which a Golgi
localization signal within the Gn protein causes these heterodimers to traffic to the Golgi
apparatus. Viral factories are formed that function as scaffolds for genome replication
9

and formation of new RNPs. These RNPs then traffic to the Golgi membranes where
the Gc-Gn heterodimers have accumulated, and interaction between RNPs and Gc-Gn
heterodimers is thought to trigger assembly and budding of bunyavirus virions into the
Golgi membranes. The nascent virions traffic in exocytic vesicles from the TGN to the
plasma membrane, where these vesicles fuse and release the virions. Evidence for
most of these steps of the bunyavirus replication cycle consists of immunofluorescence
or electron microscopy visualization of virus proteins or particles within infected cells,
and the viral and host factors responsible for these processes remain largely undefined.

10

Figure 1-1. Bunyavirus replication cycle. Binding of the viral glycoprotein to a
cellular receptor induces endocytosis and entry into an early endosome. Acidification of
the endosome causes Gn and Gc to dissociate and RNPs are released following Gcmediated fusion. Viral tubes form in close association with the Golgi apparatus, rough
endoplasmic reticulum, and mitochondria and serve as a hub for viral transcription and
translation. Gn-Gc heterodimers accumulate in the Golgi, the site of virus assembly and
budding. Infectious virions traffic in vesicles to the plasma membrane, where they fuse
and are released.
11

TOXIN ENTRY OVERVIEW
The strategies used by bacterial toxins to enter mammalian cells share many
common themes with the entry of viruses. Many bacterial species that cause human
disease secrete toxins that modify host cellular function to benefit the pathogen, and
most of these secreted toxins must access the cytosol to interact with their host target.
Common cellular targets of secreted bacterial toxins include those that regulate host
protein synthesis, immunomodulatory functions, and cell morphology.
Some bacterial species have evolved dedicated secretion systems to inject
toxins through both the bacterial membranes as well as the host plasma membrane and
deliver them directly to the cytosol, such as Helicobacter pylori, which uses its type IV
secretion system (a large needle-like structure expressed by some Gram-negative
bacteria) to inject effector proteins and DNA into the host cell (41). Intracellular bacteria
that reside in phagosomes or other compartments are able to instead secrete toxins into
the cytosol via translocation across that compartment’s membrane.

A number of

species of extracellular bacteria secrete toxins that enter the surrounding host cells
independent of such systems, however. Many of these secreted toxins (such as C.
difficile TcdB, diphtheria toxin, Shiga toxin, pertussis toxin, and cholera toxin) belong to
the general class termed AB toxins, so named for their two-component structure. The A
subunit is the active component that interferes with host cell function (typically
enzymatically) and the B subunit is the binding component responsible for attachment
and entry into the host cell. Stoichiometry varies amongst the AB toxins: some (like
TcdB and diphtheria toxin) are single-chain toxins, while others are organized into AB5
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structures (Shiga toxin and cholera toxin), binary structures (anthrax toxin), or tripartite
structures (cytolethal distending toxin) [reviewed in (42)].
For these secreted toxins, just as with infectious virions, the first step of gaining
access to the host cell is to bind to the cell surface via attachment factors and/or
receptors, and to then either directly enter by forming a pore in the plasma membrane or
hitch a ride on its receptor and be endocytosed. Like viral fusion proteins, toxins rely on
a “trigger” from the host cell in order to effect a change in the toxin that enables it to gain
access to the host cytosol. This is often accomplished in the acidifying endosomes via
proteolytic cleavage of the toxin and/or pH-induced conformational changes, which can
then form a pore through the endoplasmic membrane. The other main route of entry is
to “reverse traffic” through the host secretory pathway to gain access to the ER, where
the toxin can take advantage of pre-existing protein channels in order to bypass the
need for pore-forming capabilities (42). Those toxins that utilize retrograde transport
through the Golgi into the ER lumen often have evolved domains with sequences similar
to ER retrieval (KDEL) sequences in order to hitchhike along the cell’s existing pathway
for ER retrieval. Once they’ve arrived at the ER lumen, there are multiple strategies for
escape that have been described. One is the use of the Sec61 translocon, a channel in
the ER membrane that can function bidirectionally. Another strategy (used by cholera
toxin) is to “disguise oneself” as a misfolded protein and be transported out of the ER via
the ER-associated degradation (ERAD) machinery (43).
The specific cellular entry route of toxins varies depending upon the identity of
the receptor to which the toxin has initially bound at the cell surface. Therefore, these
toxins can enter through clathrin-mediated endocytosis (as anthrax toxin does after
binding to its receptors), through multiple pathways, including caveolae-dependent and 13

independent, as well as clathrin-dependent and -independent endocytic routes (as
cholera toxin does after binding to its receptor, the ganglioside GM1), or even utilize all
of the cell’s available endocytic pathways, as ricin toxin does by binding to terminal
galactose residues on a variety of glycoproteins and glycolipids (44–50). For those
toxins that gain access to the cytosol by forming pores in endosomes, the pH change as
the endosome is acidified can trigger proteolytic cleavage of the toxin and/or
conformation changes within toxin subunits. These pore-forming domains of the toxins
then form channels within the vesicle membrane, allowing the catalytic domains to pass
through and access the cytosol. The conformation of these catalytically active domains
of the toxin may change (back) within the more neutral pH of the cytosol.
Once bacterial toxins, via any of these mechanisms discussed, have gained
access to the host cell cytosol, they efficiently target a huge variety of host cellular
processes with the overall goal of increasing pathogenesis and survival of the bacteria.
For example, pertussis toxin has been shown to modulate the host immune and
inflammatory responses via mechanisms such as inhibition of chemokine release
[reviewed in (51)]. Because the activity of these secreted toxins are often so critical to
the pathology of their bacteria of origin, understanding (and blocking) their route of entry
is a major objective of medical research and is key to our ability to effectively treat many
bacterial diseases.
CLOSTRIDIUM DIFFICILE TOXIN B
The anaerobic bacterium Clostridium difficile causes severe antibiotic- and
hospital-associated diarrhea and pseudomembranous colitis. C. difficile infection can
lead to septic shock, perforation of the intestine, and toxic megacolon, and is fatal for
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about 9% of patients (52). Rates of C. difficile colitis have been increasing: from 2005 to
2010 there was a 47% increase compared to the five years prior (53) and the CDC
estimated in 2011 that there were 500,000 cases of C. difficile infection in the United
States (54). Spore formation by the bacterium and worsening resistance to treatment
have hindered sterilization, prevention, and treatment efforts.
C. difficile secretes two main virulence factors that are responsible for its
pathogenesis: TcdA and TcdB, both large toxins of the general AB class organization.
TcdB has been shown to be approximately 100-1000 times more cytotoxic than TcdA,
and is believed to be responsible for most of the severe disease symptoms associated
with C. difficile infection (55–57). TcdB is 270 kDa and comprises four domains, as
schematized in Figure 1-2A. These four domains are a glucosyltransferase domain
(located at the N-terminus of the protein), a cysteine protease domain (responsible for
auto-cleavage), a translocation domain (including a hydrophobic region), and a receptor
binding domain containing a combined repeat oligopeptides (CROP) region, which is
involved in binding and attachment at the cell surface.
The current model of TcdB entry into mammalian cells (see Figure 1-2B) involves
initial attachment at the cell surface (mediated by the receptor binding domain) followed
by endocytosis.

Acidification of endosomes is thought to induce a conformational

change

toxin,

in

the

leading

to

pore

formation

and

translocation

of

the

glucosyltransferase and cysteine protease domains into the cytosol (58). Autocatalytic
cleavage of the glucosyltransferase domain by the protease domain (in response to host
cell cofactors) then allows the toxic glucosyltransferase domain to interact with its target
Rho GTPases in the cytosol (59). TcdB has been shown specifically to glucosylate
RhoA (at Thr-37), Rac1 (at Thr-35), and Cdc42 (at Thr-35), although this varies by
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bacterial strain (60). Glucosylation of these Rho GTPases disrupts the numerous cell
processes that they control, including cell polarity, vesicle trafficking, and microtubule
and actin cytoskeletal regulation. TcdB-treated cells rapidly lose their mophology (round
up) and eventually undergo apoptosis.
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Figure 1-2. Structure and entry of TcdB toxin. (A) The structure of TcdB toxin. GTD:
glucosyltransferase domain, CPD: cysteine protease domain, PFR: pore-forming region,
TMD: translocation domain, RBD: receptor binding domain, CROPs: combined repetitive
oligopeptides. (B) The intoxication process of TcdB: binding at the cell surface (1) is
followed by receptor-mediated endocytosis (2). Acidification of the endosome induces a
conformational change in the toxin that results in formation of a pore (3). Autocatalytic
cleavage and release of the GTD (4) leads to glucosylation of Rho GTPases (5) which
are thereby inactivated.
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At the time of my TcdB screen, no receptors had been identified and the host
factors involved in the early entry steps of the toxin were very poorly characterized.
Toxin entry was shown to be blocked by pre-treatment with dynasore (a dynamin
inhibitor) as well as expression of dominant-negative Eps15 (a component of clathrincoated pits) and by pre-treatment with chlorpromazine (an inhibitor of clathrin-mediated
endocytosis), but not by expression of plasmids encoding dominant-negative Caveolin-1,
indicating that toxin entry is both dynamin- and clathrin-dependent (61). However, most
published work looking at TcdB entry has focused on describing mutations or truncations
of the toxin that block its activity. The readout for toxin entry / activity in most literature is
a visual cell-rounding assay, or sometimes detection of glycosylation of Rac1 in cell
lysates. A detailed understanding of the endocytic route of TcdB entry, its trafficking
within the cell, its site of translocation, and the host factors upon which it relies during
these processes is still badly needed.
SCREENING INTRODUCTION
High-throughput and unbiased screening techniques are a powerful tool for
identifying host cellular factors that are required by viruses and toxins. In recent years,
such screening techniques have been employed successfully to better characterize
many different aspects of host-pathogen interactions. Here follows an overview of the
primary screening strategies and examples of their use in identifying host factors
impacting bunyavirus infection and toxin entry.
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SMALL MOLECULE SCREENING
The lack of vaccines and therapeutics for many emerging viral and bacterial
diseases has renewed interest in the screening of small molecule inhibitors, including
the repurposing of clinically-approved pharmacologics. In 2016, Islam and colleagues
used a high-throughput drug screen to identify compounds which potently inhibited
RVFV infection, based upon a replication-competent recombinant virus lacking the NSs
gene and bearing a fluorescent reporter (62). This study yielded six compounds (out of
approximately 28,000 screened) that exhibited inhibitory activity at low concentrations
with minimal cytotoxicity. Follow-up studies will be required to determine the mechanism
of action of these compounds and their potential suitability as therapeutic agents against
RVFV and perhaps other bunyaviruses. Bender et al. used the National Institutes of
Health Clinical Collection as well as a library of non-FDA-approved bioactive compounds
that are considered to be clinically safe in order to screen for an inhibitor of C. difficile
TcdA and TcdB toxins (63). Their screen identified the compound ebselen (currently in
clinical trials for unrelated conditions) as a potent inhibitor of the cysteine protease
domain of both toxins, and verified in a mouse model that it decreases pathology of C.
difficile infection.
Advances in inhibitor drug screening have also included methods to study the
interactions between compounds that may be able to synergistically restrict viral
infection. In 2012, Tan and colleagues described multiplex screening for interacting
compounds (MuSIC), an analysis of all of the possible pairs of 1,000 commercially
available compounds that were FDA-approved or clinically tested (64). The authors
identify anti-inflammatory drugs as a group that synergistically enhanced anti-HIV activity
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and informed drug-interaction network formation. Such screening methods may uncover
previously uncharacterized therapeutic options within the pool of clinically-tested or approved drugs.
BIOCHEMICAL APPROACHES
Valuable insight into the host-pathogen relationship can also be gleaned from
interrogating physical interactions between pathogen and cellular proteins. The most
widely-used applications for probing protein-protein interactions are yeast two-hybrid
(Y2H) and affinity purification followed by mass spectrometry (AP/MS) techniques. Y2H
screens utilize a reporter gene whose expression depends upon the activity of a
transcription factor whose modular binding and activation domains have been fused,
respectively, to bait and prey proteins. The protein of interest whose interacting partners
are to be probed is the bait, and the prey proteins are typically libraries of proteins (or
protein fragments) covering the genome of the organism of interest.

These hybrid

proteins are then introduced into cells, and if the bait and prey proteins interact, the
binding and activation domains come into close enough proximity to reconstitute
transcription factor activity and effect the expression of the reporter gene.

During

AP/MS, a bait protein of interest is pulled down via affinity for an antibody against either
the protein itself or a tag to which it has been fused. One specialized type of such a tag
is the two-part tag used in tandem affinity purification (TAP) techniques. The TAP tag
comprises a Protein A tag and calmodulin binding peptide (CBP) tag separated by a
recognition sequence that is specific to the Tobacco etch virus (TEV) protease. Protein
complexes are purified by first capturing with the terminal Protein A tag, then using the
TEV protease to cleave and release bound complexes and expose the CBP, followed by
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a second affinity purification step of immobilization on calmodulin. This dual-affinity
approach reduces the possibility of co-purification resulting from non-specific
interactions.
Bunyavirus proteins have been used in protein-protein interaction screens to find
interacting partners, particularly for the nonstructural protein NSs, which is known to be
critical for viral defense against the host’s type I interferon response.

Leonard and

colleagues performed yeast two-hybrid screening of a HeLa cDNA library using the
BUNV NSs protein as bait (65). They identified MED8, a component of the Mediator
complex, as a target of NSs during infection.

Mediator is a key regulator of RNA

polymerase II transcriptional activity, and the domain of NSs responsible for this MED8
interaction contains a motif that is highly conserved among orthobunyaviruses,
suggesting that this interaction represents an important defense mechanism used by the
virus to dismantle the host interferon response. In 2012, Rönnberg et al. used yeast
two-hybrid screening with a mouse embryo cDNA library with the hantaviruses Puumala
virus (PUUV) and Tula virus (TULV) NSs proteins as bait (66). From these two screens,
65 total host cellular proteins were identified as hantavirus interacting partners, with
considerable overlap between the lists of partners for the two hantaviruses. This dataset
provided insight into potential, previously-undescribed roles for NSs during infection,
including regulation of apoptosis and interaction with proteins of the integrin complex.
An extensive survey of viral-host protein-protein interactions by Pichlmair and
colleagues in 2012 used as bait a panel of 70 viral open reading frames (ORFs) selected
for their roles in defending against the host innate immune response (67).

The

bunyavirus ORFs included in the panel were the NSs of RVFV, LACV, and Sandfly fever
Sicilian virus (SFSV). These 70 viral ORFs were expressed within a HEK293 cell line
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and then TAP followed by liquid chromatography tandem mass spectrometry (LCMS/MS) was used to identify 579 interacting host proteins. Within these hits, there was
an overrepresentation of proteins known to be involved in innate immunity, and
specifically they noted an enrichment within the interacting partners of the negativesense single-strand RNA for host proteins that may promote processing of viral RNA
transcripts or prevent detection and degradation of these transcripts. In 2014, a followup study was published by Kainulainen et al. examining the interaction between RVFV
NSs and the host F-box protein FBXO3 (68). FBXO3, which is a component of an E3
ubiquitin ligase, was shown to be recruited by NSs to effect the degradation of p62, a
subunit of the general transcription factor TFIIH. Depletion of FBXO3 was unable to fully
rescue interferon induction in RVFV-infected cells, did not affect the ability of NSs to
degrade the interferon-induced antiviral effector dsRNA-dependent protein kinase R
(PKR), and did not significantly impact viral replication. The authors therefore concluded
that this FBXO3-mediated degradation of p62 is partially, though not completely,
responsible for the ability of NSs to suppress the host interferon response.

These

findings highlight the capacity of protein-protein interaction studies for uncovering host
factors that might not have been detected by gene-disruption or gene-depletion
screening strategies, which usually depend upon robust viral replication or host cell
survival phenotypes.
To my knowledge, no protein-protein interaction screens have been performed
using any clostridial toxins. However, the Helicobacter pylori cytotoxin VacA was used
as bait in a yeast two-hybrid screen to identify its interaction with the cellular protein
receptor for activated C-kinase (RACK1), demonstrating the potential of such
approaches to identify host protein interacting partners of bacterial toxins (69).
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GENETIC APPROACHES
RNA interference (RNAi) technology was the first of a new generation of highthroughput screening approaches applied to the study of host-pathogen interactions.
Examples of its use include the pioneering screens by Cherry, et al. to uncover a role for
host organelle-reshaping and ribosomal proteins in Drosophila C virus replication (70,
71), a series of 2008 studies from multiple labs that identified many host factors
necessary for human immunodeficiency virus (HIV)-1 replication (72–74), and the
characterization in 2009 by Brass and colleagues of IFITM proteins as restriction factors
for influenza, West Nile, and dengue viruses (75). For this screening technique, the
incorporation of small interfering RNAs (siRNAs) into the RNA-induced silencing
complex (RISC) effects the cleavage of target cellular mRNA and consequent
knockdown of gene product expression. These siRNAs can be either directly introduced
into the cell, or derived from supplied precursors: long double-stranded RNAs (dsRNAs)
or short hairpin RNAs (shRNAs) that are then processed by cellular machinery. The
availability of increasingly robust genome-wide libraries for RNAi screening has greatly
increased its popularity as a high-throughput, unbiased screening platform.
Within the bunyavirus field, a 2013 RNAi screen by Hopkins et al. in Drosophila
cells used dsRNAs targeting more than 13,000 genes, identifying 124 that restricted
infection by the phlebovirus Rift Valley Fever virus (RVFV), with genes involved in DNA
replication, the cell cycle, and mRNA metabolic processing being significantly enriched
(76). Among these were the catalytic component of the mRNA decapping machinery
(Dcp2) as well as two decapping activators, DDX6 and LSM7.

Bunyaviruses “cap-

snatch” by cleaving nucleotide sequences from the 5′ ends of host mRNAs in order to
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prime the viral genome for transcription, and the authors showed that RVFV specifically
cap-snatches the 5′ ends of Dcp2-targeted mRNAs, as did La Crosse virus (LACV), a
member of the Orthobunyavirus genus. The year after, Meier and colleagues performed
a screen using Uukuniemi virus (UUKV) in HeLa cells expressing the surface lectin
CD209, which is an attachment factor for UUKV in dendritic cells (77). Two independent
genome-wide siRNA libraries were used from two manufacturers: one library with four
unpooled siRNAs per gene and one library with four unpooled siRNAs per gene. In both
screens the v-SNARE VAMP3 was identified as a host factor required for the entry of
UUKV. The importance of VAMP3 was also indicated by virtue of its being a target for
the endogenous microRNA miR-142-3p, a microRNA identified as impacting infection
after analysis of the seed sequences of the siRNAs used for screening. The authors
examined incoming UUKV virions trafficking through the endocytic pathway and noted
increasing colocalization of virions with VAMP3 as they moved within vesicles through
the cytoplasm. At 20 min after internalization, maximum colocalization between UUKV
virions and VAMP3 was observed within vesicles positive for lysosomal-associated
membrane protein 1 (LAMP1), a marker for late endosomes and lysosomes. In VAMP3depleted cells, incoming virions failed to reach these LAMP1-positive vesicles, indicating
that their trafficking was arrested at an earlier endosomal compartment. These data
informed our understanding of the host cellular machinery required for maturation of
endosomal compartments and for the fusion of late-penetrating viruses within the acidic
environment of late endosomes.
In 2015, Yuan and colleagues transfected HeLa cells with a microRNA-adapted
shRNA (shRNAmir) library and challenged them with TcdB toxin to screen for clones that
were resistant to toxin-induced cell rounding (78). Their screen identified chondroitin
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sulfate proteoglycan 4 (CSPG4) as a cell surface receptor that was capable of mediating
internalization of TcdB in HeLa cells.

Further, the authors demonstrated a direct

interaction between the N-terminus of CSPG4 and the C-terminus of TcdB, at a region of
the toxin’s receptor-binding domain immediately adjacent to the CROP domain. Two
important pieces of evidence from this study supported the conclusion, however, that an
additional cellular receptor for TcdB exists. First, the resistance of CSPG4-/- HeLa cells
to cell rounding was only observed at low concentrations of the toxin, and even slightly
increasing the concentration of TcdB caused a loss of phenotype. Second, treatment of
CSPG4 knockout mice with TcdB showed a decrease in plasma IL-8 levels (relative to
WT mice) but no effect on animal survival.

The authors suggested that the CROP

domain was likely responsible for binding of another receptor.
The arrival of haploid screening in human cells, first described by Carette and
colleagues in 2009, offered a loss-of-function forward genetic approach as a powerful
alternative to traditional siRNA-based depletion screens (79, 80). In these screens, null
alleles are generated in mammalian haploid cells using insertional mutagenesis, and the
resulting cellular library is challenged by a selective agent such as a virus or toxin.
Surviving cells, which presumably lack a gene required by the selective agent as a
consequence of retroviral insertion, are pooled and deep sequencing is used to map the
insertion sites of the mutagenizing lentivirus.

Statistical analysis identifies the

enrichment of insertion sites within the surviving (selected) population compared to the
original mutant library, yielding a list of genes whose disruption confers a resistance
phenotype. This approach identified the homotypic fusion and vacuole protein sorting
(HOPS) tethering complex and the endo/lysosomal cholesterol transporter protein
Nieman-Pick 1 (NPC1) as essential host factors for Ebola virus (EBOV) entry, and
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uncovered the receptor-switching process of Lassa virus (LASV) as it engages first its αdystroglycan receptor at the cell surface and then later its intracellular receptor, the
lysosomal transmembrane protein LAMP1 (81–83).

These studies have provided

potential antiviral targets, as well as insight into the molecular determinants of host
tropism, for these important human pathogens.
In 2014, our lab – in collaboration with the lab of Paul Bates – used a
recombinant vesicular stomatitis virus (VSV), in which the Andes virus (ANDV)
glycoproteins are expressed on the VSV core, to identify cellular host factors required for
ANDV entry (84). This rVSV-ANDV was used to challenge a human haploid mutant
library and multiple members of the sterol regulatory pathway were identified as
impacting ANDV entry. This dependence upon cholesterol was validated using live wildtype ANDV, a member of the New World hantaviruses that are causative agents of
hantavirus pulmonary syndrome (HPS). Cholesterol requirement during viral entry was
verified through the use of Chinese hamster ovary (CHO) knockout cell lines,
pharmacological inhibitors, siRNA depletion, and transcription activator-like effector
nuclease (TALEN) disruption of members of the sterol regulatory pathway, as well as by
direct depletion of cholesterol in the cellular membranes.

Virus binding at the cell

surface was unaffected, but an internalization defect was observed within cells that lack
a functional sterol regulatory pathway. Interestingly, this exquisite dependence upon
cholesterol is not shared by all members of the Buyaviridae family (unpublished data).
The following year, Kleinfelter and colleagues independently confirmed these findings
and extended the cholesterol-dependence phenotype to members of both the Old World
and New World hantavirus clades (85). Cholesterol depletion was shown to significantly
delay virus internalization, and to inhibit the ability of virions to fuse with cellular
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membranes. This finding is intriguing, as the pH requirement for ANDV implicates it as a
late-penetrating virus, but the liposome fusion results from Kleinfelter et al. suggest that
ANDV may require a greater cholesterol concentration than what is present in the
membranes of late endosomes.

Detailed mechanistic studies will be needed to

reconcile this, and to determine whether hantaviruses somehow modulate endosomal
cholesterol composition, fuse specifically at cholesterol-rich microdomains, or whether
cholesterol plays some other role during virus-membrane fusion.
Human haploid genetic screening was used in 2014 by Schorch and colleagues
to examine the entry of Clostridium perfringens toxin TpeL, a recently-described
glycosylating toxin that is structurally similar to TcdB but lacks the CROP domain (86).
This screen identified low-density lipoprotein receptor-related protein 1 (LRP1) as a
binding partner and endocytosis-mediating receptor for TpeL toxin. However, TcdB toxin
lacking the CROP domain was capable of entering WT MEF cells and MEFs lacking
LRP1 with equal efficacy. This indicate that the non-CROP region in the C-terminus
receptor-binding domain of TcdB (which is approximately 50% similar to the
corresponding region of TpeL) does not utilize LRP1 as a receptor for TcdB in this cell
type.
The following year, LaFrance et al. generated a mutagenized library of Caco-2
cells using a retroviral gene-trap vector that confers resistance to neomycin (87). They
challenged this library with TcdB and identified two clones with mutations in the polio
virus receptor-like 3 (PVRL3) gene, a cell surface protein and member of the nectin
family of adhesion molecules.

Knockdown of PVRL3 in Caco-2 cells (by shRNA)

conferred partial resistance to TcdB, as assayed by quantification of ATP to indicate cell
viability. In HeLa cells, shRNA knockdown and CRISPR-mediated disruption of PVRL3
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also increased cell viability after TcdB challenge, but it did not protect cells from the
rounding activity of the toxin.

Perplexingly, the authors did not show cell-rounding

results in Caco-2 cells. They did look at protein expression levels (by Western blot) of
both CSPG4 and PVRL3 in Caco-2 cells and HeLa cells, and found that CSPG4 is only
expressed in HeLa cells, whereas PVRL3 is expressed in both cell types, though at a
higher level in Caco-2 cells. The role of PVRL3 in TcdB entry of Caco-2 cells was
further characterized by demonstration of direct binding of purified PVRL3 and TcdB
proteins, as well as by increased cell ATP levels in the presence of TcdB treatment
when the cells were pre-treated with anti-PVRL3 antibodies. PVRL3 and TcdB were
also shown to colocalize in human colon explant tissue. These data indicate a role for
PVRL3 in TcdB entry of colonic epithelial cells.
Just recently, a TcdB screen was published using a CRISPR sgRNA library
introduced into HeLa cells that stably express the Cas9 endonuclease (88). The three
top hits from this screen were UDP-glucose pyrophosphorylase (UGP2), an ezyme that
produces the glucose required by TcdB for its glucosylation of target GTPases; CSPG4;
and the protein frizzled class receptor 2 (FZD2), which is a member of the Frizzled family
of Wnt signalling receptors.

HeLa cell lines lacking FZD2 (via CRISPR-mediated

disruption) were approximately 15-fold more resistant to TcdB lacking the CROP
domain, but were not more resistant to full-length TcdB. However, when these cells
were also disrupted at the loci encoding FZD1 and FZD7 proteins, the combined
FZD1/2/7-/- HeLa cells were 10-fold more resistant to full-length TcdB than WT cells.
The authors used truncation mutants of TcdB to show that CSPG4 functions as a
CROP-dependent receptor, whereas Frizzled proteins act as CROP-independent
receptors.

Rescue experiments using introduction of CSPG4 and FZD2 as well as
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competition experiments using pre-treatment of cells with the binding domains of these
two proteins demonstrated that CSPG4 and Frizzled proteins act as non-competetive
receptors for TcdB and that their relative contribution to toxin entry depends upon their
cell-type-specific expression levels.
CONCLUSION
In December of 2015, the World Health Organization published its Workshop on
Prioritization of Pathogens executive summary, which listed the emerging diseases most
likely to cause severe outbreaks in the near future (89). Of the ten diseases named,
three are caused by bunyaviruses: Rift Valley fever, Crimean-Congo hemorrhagic fever,
and severe fever with thrombocytopenia syndrome. Concern is likewise mounting about
the increasing incidence, virulence, and antibiotic-resistance of C. difficile infection
worldwide (90).

Within the United States, C. difficile infects half a million people

annually, killing 29,000 each year, is the most common cause of nosocomial infections,
and costs $4.8 billion dollars per year in healthcare expenses for acute care facilities,
according to the CDC.

A better understanding of the molecular details of the

pathogenesis of these diseases is urgently needed in order to inform the development
and application of therapeutic interventions. Interesting questions also remain to be
answered about many of the fundamental cell biological processes involved in the entry
of bunyaviruses and C. difficile Toxin B. For these reasons, my dissertation research
applied high-throughput screening technology to interrogate the interactions of these
fascinating and important pathogens with their mammalian host cells.
The data that follow in Chapters 2 and 3 summarize the results of two
independent screening projects, each utilizing a strategy of forward genetic screening in
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a mutagenized human haploid cell library. The first was performed with the vaccine
strain of RVFV, and identifies glycosaminoglycans as a bunyavirus attachment factor on
some cell types. The second screen was done by sequential challenge of the mutant
library with TcdB, and indicates a role for an actin polymerization-regulating complex in
the entry of this toxin.
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CHAPTER 2: A HAPLOID GENETIC SCREEN IDENTIFIES
HEPARAN SULFATE PROTEOGLYCANS SUPPORTING
RIFT VALLEY FEVER VIRUS INFECTION

ABSTRACT
Rift Valley fever virus (RVFV) causes recurrent insect-borne epizootics
throughout the African continent, and infection of humans can lead to a lethal
hemorrhagic fever syndrome. Deep mutagenesis of haploid human cells was used to
identify host factors required for RVFV infection. This screen identified a suite of
enzymes involved in glycosaminoglycan (GAG) biogenesis and transport, including
several components of the cis-oligomeric Golgi (COG) complex, one of the central
components of Golgi complex trafficking. In addition, disruption of the previouslyuncharacterized gene PTAR1 led to RVFV resistance as well as reduced heparan
sulfate surface levels, consistent with recent observations that PTAR1-deficient cells
exhibit altered Golgi complex morphology and glycosylation defects. A variety of
biochemical and genetic approaches were utilized to show that both pathogenic and
attenuated RVFV strains require GAGs for efficient infection on some, but not all, cell
types, with the block to infection being at the level of virion attachment. Examination of
other members of the Bunyaviridae family for GAG-dependent infection suggested that
the interaction with GAGs is not universal among bunyaviruses, indicating that these
viruses, as well as RVFV on certain cell types, employ additional unidentified virion
attachment factors and/or receptors.
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INTRODUCTION
Rift Valley fever virus (RVFV) is a member of the Bunyaviridae family of viruses
that cause emerging infections that threaten both human and livestock populations on
several continents (1). Bunyaviruses have a tripartite, negative-sense RNA genome and
are frequently transmitted by insects (1). RVFV can be transmitted by mosquitoes or by
exposure to infected tissues and body fluids and is considered endemic in much of
Africa (2). In humans, RVFV can cause an acute fever leading to complications such as
kidney failure and, in about 1% of cases, a lethal hemorrhagic fever (3, 4). In addition,
RVFV spreads rapidly across infected herds of livestock and can cause significant
mortality in infected animals (5, 6).
We took a genetic approach to identify host factors that are required for RVFV
infection in vitro by employing an insertional mutagenesis screen using HapI cells, a
human haploid cell line. By utilizing a retroviral gene trap, gene-inactivating insertion
sites can be efficiently mapped with deep sequencing technology (7). This approach has
successfully uncovered host factors required by a variety of pathogens, including
viruses, bacteria, and bacterial toxins (8–12). When gene trap-mutagenized HapI cells
were challenged with RVFV and the surviving cells were analyzed, there was an
enrichment of sites of insertion into multiple genes involved in glycosaminoglycan (GAG)
biosynthesis as well as genes for subunits of the cis-oligomeric Golgi (COG) complex
and PTAR1. We confirmed the requirement for heparan sulfate during infection with
RVFV isolates with a variety of genetic and biochemical perturbations, consistent with
the findings from de Boer et al. (13). We now show that the dependency on heparan
sulfate during RVFV infection is consistent across a representative panel of primary
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RVFV isolates and, by employing vesicular stomatitis virus (VSV)-based pseudovirions,
that utilization of GAGs by RVFV during infection occurs at the step of entry. We were
able to identify, using a quantitative binding assay, virus attachment to be the specific
entry step affected. However, the dependence of RVFV on GAGs for efficient infection
was cell type dependent. Surfen (a small-molecule antagonist that binds to heparan
sulfate) inhibited infection of HapI and SNB-19 cells by replication-competent RVFV, yet
surfen did not impact infection of several other cell lines by RVFV, even though it
efficiently blocked infection by herpes simplex virus 1 (HSV-1), a virus that depends
upon heparan sulfate for efficient infection in vitro. Thus, while GAG interactions do
significantly enhance RVFV infection in some contexts, other virus attachment factors
must also exist and/or RVFV utilizes GAG structures that do not efficiently interact with
surfen.
MATERIALS AND METHODS
Cells and viruses. HapI cells (7) and the derived mutant cell lines were grown in
Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% (vol/vol) fetal
bovine serum (FBS), 2 mM l-glutamine, 1 mM sodium pyruvate, 10 units/ml penicillin,
and 100 μg/ml streptomycin. HEK 293T, Vero E6, C6/36, L, and sog9 cells (a generous
gift from Frank Tufaro) were grown in Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% (vol/vol) FBS, 2 mM l-glutamine, 10 units/ml penicillin, and 100
μg/ml streptomycin. The following strains of RVFV were used in this study: MP-12, ZH501, Kenya 9800523, and Kenya 2007002444. MP-12 was propagated in MRC-5 cells
(at the University of Pennsylvania) or Vero E6 cells (at USAMRIID), while the ZH-501
and the Kenyan strains were propagated in Vero E6 cells. Viral titers on Vero E6 cells
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were determined by plaque assay. Crimean-Congo hemorrhagic fever virus (CCHFV)
strain IbAr10200 was propagated in CER cells, and viral titers on CER cells were
determined. HSV-1 strain k-GFP (a generous gift from Nigel Fraser, University of
Pennsylvania) was propagated in Vero E6 cells. Studies using RVFV ZH-501 were
conducted in a biosafety level 3 laboratory at USAMRIID, whereas infections using the
Kenyan RVFV strains and CCHFV were performed in a biosafety level 4 laboratory at
USAMRIID. Appropriate safety protocols were followed, and personal protective
equipment was worn while conducting experiments in the high-containment laboratories.
The generation of PTAR1-deficient HapI cells was described before (14).
Insertional mutagenesis. HapI cells were mutagenized with a retroviral gene
trap as described in reference 11 and exposed to strain MP-12. Surviving clones were
expanded for genomic DNA isolation. Subsequently, gene trap insertion sites were
amplified using an inverse PCR, submitted for parallel sequencing (Illumina HiSeq
2000), and aligned to the human genome (hg18) (10). Genes significantly enriched for
gene-trap insertions compared to the sequences of an unselected control cell population
were identified using a one-sided Fisher's exact test as described in reference 11.
RVFV pseudovirion production. To assess the specific role of GAGs in RVFV
attachment and entry, as opposed to downstream replication events, we used a VSV
pseudovirion system (15, 16) in which the VSV glycoprotein gene G was deleted from
the viral genome (VSVΔG) and replaced with a reporter gene, either Renilla luciferase
(VSVΔG-rLuc) or red fluorescent protein (VSVΔG-RFP). To generate VSVΔG
pseudovirions possessing RVFV glycoproteins (or those of other viruses), the
glycoproteins were provided in trans via an expression vector to cells transduced with
the VSVΔG core. HEK 293T cells seeded in 10-cm2 plates were transfected with
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pCAGGS RVFV ZH-548 M using the Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer's instructions. This construct is codon optimized for expression in
human cells and contains only the coding region of the M segment starting at the fourth
ATG start codon, which omits the NSM coding region. At between 16 and 20 h after
transfection, cells were transduced with VSVΔG pseudovirions bearing VSV G. After
adsorption of pseudovirions for 1 h, cells were carefully rinsed four times with warm
phosphate-buffered saline (PBS) containing calcium and magnesium, and then the
medium was replaced with complete DMEM supplemented with 25 mM HEPES. Cell
culture supernatants were collected 24 h later, clarified by low-speed centrifugation for
30 min at 4°C, filtered (pore size, 0.45 μm), and then aliquoted for storage at −80°C.
Andes virus (ANDV) and Hantaan virus (HTNV) pseudovirions were generated in the
same fashion.
Virus infections. To compare the ability of diverse RVFV strains or CCHFV to
infect HapI cells and the derived mutant cell lines, we utilized a high-content imagingbased infection assay. Each cell line was seeded at a density of 1 × 104 cells per well in
Greiner black well, clear-bottom 96-well plates. At 24 h after seeding of the cells, the
culture medium was removed and the cells were infected with viruses diluted in
complete IMDM. The virus inocula were not washed off and the plates were incubated at
37°C until approximately 18 to 20 h postinfection. At this point, the cell culture medium
was removed from the cells and the plates were immersed in 10% neutral buffered
formalin for 24 h to fix the cells and render virus noninfectious prior to removal from the
high-containment laboratories. Prior to immunostaining for viral antigens, residual
formalin was removed from the plates, and they were then rinsed extensively with
phosphate-buffered saline (pH 7.4). The cells were permeabilized for 15 min with a
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solution of 0.1% (vol/vol) Triton X-100 in PBS, and then the permeabilization buffer was
rinsed away by additional PBS washes. The cells were blocked for at least 1 h using a
3% (wt/vol) solution of bovine serum albumin in PBS. Purified monoclonal antibodies
specific for RVFV N (R3-1D8) or CCHFV N (9D5-1-1A) were diluted 1:1,000 in blocking
buffer and then added to the cells for 1 h, followed by extensive washing with PBS. Antimouse immunoglobulin Alexa Fluor 568-labeled secondary antibody was diluted 1:2,000
in blocking buffer and then added to the cells for 1 h, followed by extensive washing in
PBS. The cells were then counterstained with a solution of Hoechst 33342 (nuclei) and
HCS CellMask deep red stain (total cell), each of which was diluted 1:10,000 in PBS.
This counterstain solution was maintained on the plates during high-content imaging.
Automated image acquisition was performed using an Operetta high-content imaging
system. Three exposures (one for each of the fluorophores) in five separate fields were
acquired in each well using a 20× air objective and a Peltier cooled 1.3-megapixel
charge-coupled-device camera. The fluorophores were illuminated using a 300-W xenon
arc light source and excitation (EX) and emission (EM) filters for the following: Alexa
Fluor 568 (EX/EM), Hoechst 33342 (EX/EM), and HCS CellMask deep red (EX/EM).
Image segmentation and analysis were performed using Harmony (version 3.0) software
and standard scripts. These algorithms were used to first delineate nuclear and cell
boundaries and then identify viral antigens by Alexa Fluor 568 staining. To calculate
percent infection per image field, the number of cells exhibiting an Alexa Fluor 568 mean
fluorescence intensity greater than the mean intensity for uninfected control wells was
divided by the total cell number defined by Hoechst 33342 nuclear staining. For each
well, the Harmony software reported the mean percent infection of the five fields. On
average, 1,500 to 5,000 cells were analyzed per well. In each independent experiment,
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at least 4 individual wells were analyzed for each cell line. Infections with VSVΔG-RFP
pseudovirions or HSV-1 were carried out at a low volume for 1 h at 37°C, after which
complete DMEM or IMDM was added to the wells. Twenty-four hours later, the cells
were trypsinized, fixed in 2% paraformaldehyde and then analyzed for RFP (for VSVΔG
pseudovirions) or green fluorescent protein (GFP) (for HSV-1) expression by
fluorescence-activated cell sorting (FACSCalibur flow cytometer; BD Biosciences). For
infections in the presence of surfen (5 μM; Sigma), dextran sulfate (5 μg/ml, 5 kDa;
Sigma), or heparinase I (3 U/ml; Sigma), cells were pretreated for 1 h and, in the case of
surfen and dextran sulfate, kept in the presence of drug for the duration of the infection.
For soluble GAG competition experiments, heparin (10 and 100 μg/ml; Fisher
BioReagents) and heparan sulfate (10 and 100 μg/ml; Iduron) were preincubated with
HSV-1 or MP-12 at 25°C for 1 h. The virus and GAG solution was then allowed to
adsorb onto cells for 1 h at 37°C, after which it was rinsed 3 times with PBS containing
calcium and magnesium and cells were refed with fresh medium that did not contain
either virus or GAGs. Infections were then harvested at 8 to 10 h postinfection (hpi), and
percent infection was scored by flow cytometry, looking for either intracellular staining of
the N protein (for MP-12) or expression of the GFP reporter protein (for HSV-1). For
pseudovirion neutralization studies, RVFV and severe acute respiratory syndrome
(SARS) coronavirus antisera (a generous gift from Stuart Nichol, Centers for Disease
Control and Prevention) were preincubated with pseudovirions at the indicated dilutions
for 30 min at 37°C. The linear range of the assay was determined by performing serial
10-fold dilutions of each virus stock on each target cell type and for each detection
method used. Infection assays were typically linear over at least a 2-log-unit range of
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virus dilutions, with the virus inoculum being adjusted to achieve infection levels of
between 1 and 30%.
RVFV binding assay. Virus was diluted in DMEM (Gibco) and added to HapI
cells and the derived mutant cell lines for 1 h at 37°C. The cells were then washed four
times with PBS, and total RNA was isolated from the cells using a Qiagen RNeasy
minikit. RNA was quantified by measuring the absorbance at 260 nm, and first-strand
cDNA was generated from 1.5 μg of total RNA using a SuperScript VILO cDNA
synthesis kit (Invitrogen) according to the manufacturer's instructions. Primers specific to
the MP-12 L segment (forward L segment primer 5′-TGAGAATTCCTGAGACACATGG3′; reverse L segment primer 5′-ACTTCCTTGCATCATCTGATG-3′) were purchased
from Invitrogen, and a 6-carboxyfluorescein/MGB probe specific to the MP-12 L segment
with the sequence 5′-CAATGTAAGGGGCCTGTGTGGACTTGTG-3′ was purchased
from Applied Biosystems. Reverse transcription-PCR (RT-PCR) was then performed
using an ABI 7500 real-time PCR system (Applied Biosystems) with the following
conditions: (i) denaturation at 95°C for 20 s and (ii) 40 cycles of PCR amplification with
denaturation at 95°C for 3 s and annealing and extension at 60°C for 30 s. Data were
analyzed using the ΔΔCT threshold cycle (CT) method by calculating the change in gene
expression normalized to that of GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
as a housekeeping gene (17).
Statistical analysis. Statistical significance was calculated using a two-tailed,
one-sample t test by comparing the fold changes to the hypothetical value of 1 in Prism
software (version 5.0a; GraphPad Software). P values were not reported for conditions
where only two biological replicates were performed.
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RESULTS
An insertional mutagenesis screen for RVFV host factors in a human
haploid cell line. To identify the host factors needed for RVFV infection, 1 × 108 HapI
cells were mutagenized using a retroviral gene trap vector (11). Subsequently,
mutagenized cells were infected with the cytotoxic RVFV MP-12 strain and the surviving
cells were expanded as a polyclonal cell population. Following isolation of genomic DNA,
gene trap insertion sites were sequenced and aligned to the human genome.
Subsequently, the retroviral insertions within genes in the virus-resistant population were
counted and compared to the number of insertions within the same gene in an
unselected cell population (11). Genes significantly enriched (P < 0.001) for insertions in
the virus-selected cell population were identified (Fig. 2-1A). These contain multiple
genes encoding enzymes required for synthesis of glycosaminoglycans (refer to Fig. 21B), including the four enzymes needed for the tetrasaccharide linkage region (XYLT2,
B4GALT7, B3GAT3, and B3GALT6) (18–23), two enzymes involved in proteoglycan
chain elongation (EXT1 and EXT2) (24), and the enzyme that catalyzes both Ndeacetylation and N-sulfation during the biosynthesis of heparan sulfate (NDST1) (25).
Genes required for the synthesis (UXS1, UGDH) or transport (SLC35B2) of critical
moieties for heparan sulfate chain formation (26–28) were also enriched in cells resistant
to RVFV infection (Fig. 2-1A and B). In addition to genes directly involved in heparan
sulfate biosynthesis, several subunits of the conserved oligomeric Golgi (COG) complex
(COG1, COG2, COG3, COG4, COG5, COG7, COG8) (29) were identified from the
screen. It is known that perturbation of the COG complex attenuates O-linked
glycosylation by impairing Golgi complex function (29, 30). Another hit in this screen
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encoded UNC50, a Golgi complex-resident transmembrane protein that plays a role in
nicotinic acetylcholine receptor trafficking in Caenorhabditis elegans (31). Finally, this
screen identified the gene for prenyltransferase alpha subunit repeat containing 1
(PTAR1) to be important for RVFV infection. PTAR1 was previously shown to affect
glycosylation (11), possibly by influencing vesicular trafficking through prenylation of Rab
GTPases (14, 32). Although genes involved in vesicular trafficking could represent more
direct interactions with RVFV, the overlap of these results with those from a screen
performed for cell surface GAG expression (11) suggests a function for these genes in
the presentation of glycans at the cell surface.
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Figure 2-1. Human haploid mutagenesis screen for RVFV host factors. (A) Plot
showing genes enriched in the virus-selected population compared with their levels in an
unselected population. Each circle demarks a gene, with its y-axis coordinate
representing the false discovery rate-corrected P value and its area reflecting the
number of identified unique gene trap integrations. Genes that are significantly enriched
in the virus-selected population (P < 0.001) are colored and horizontally grouped on the
basis of their function. (B) Overview of heparan sulfate synthesis. Xyl: xylose, Gal:
galactose, GlcA: glucuronic acid, IdoUA: iduronic acid, GlcN: N-acetylglucosamine.
Genes involved in heparan sulfate synthesis that were significantly enriched in our RVFV
screen are shown in parentheses.
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GAGs are important for RVFV infection. Because the majority of genes
identified in our screen pertained to GAG synthesis, we first focused on elucidating the
role of GAGs during RVFV infection. We were able to obtain single-cell clones of genetrapped B3GAT3 (B3GAT3GT) and B4GALT7 (B4GALT7GT) and exposed these cells to
the MP-12 strain of RVFV. As shown in Fig. 2-2A, these cells were markedly resistant to
MP-12 infection. Importantly, reintroduction of the respective cDNAs completely restored
sensitivity to virus infection, indicating that the observed resistance phenotype can be
solely attributed to the gene-trapped loci (Fig. 2-2A). To determine whether the synthesis
of the O-linked tetrasaccharide linker was required for RVFV infection, we produced a
B3GAT3GT cell line stably expressing an enzymatically inactive point mutant of GlcAT-I
(D194A/D195A) (33). As with the B3GAT3GT cells stably expressing an empty vector
construct, introduction of this enzymatically inactive form of GlcAT-I into B3GAT3GT
cells did not rescue MP-12 infection (Fig. 2-2B). B4GALT7 encodes the β-1,4galactosyltransferase GalT-I, which catalyzes the enzymatic step immediately upstream
of the β-1,3-galactosyltransferase reaction in the synthesis of the GAG linker (Fig. 2-1B).
As with the B3GAT3GT cell panel, MP-12 infection also required a catalytically active
form of GalT-I (Fig. 2-2B), further suggesting that RVFV is dependent upon GAGs for
efficient infection.
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Figure 2-2. GAGs are important for RVFV infection. (A) Expression of the B3GAT3
and B4GALT7 gene products is required for strain MP-12 infection. B3GAT3 and
B4GALT7 gene-trapped (GT) HapI cells transfected and selected to stably express
empty vector (vector) or wild-type (WT) protein (rescue) were infected with MP-12, and
surviving cells were stained with crystal violet. (B) GAGs are important for diverse strains
of RVFV. B3GAT3GT and B4GALT7GT HapI cells that stably express the empty vector
(vector), the wild-type protein (rescue), or a catalytically inactive point mutant (mutant)
were infected with the MP-12, ZH-501, Kenya 980052 (Kenya 1998), and Kenya
2007002444 (Kenya 2007) strains of RVFV, and the percentage of infected cells was
normalized to the percentage of infected parental HapI cells. Bars indicate SEMs (n = 3
for MP-12, ZH-501, and Kenya 980052; n = 2 for Kenya 2007002444). *, P < 0.005; **, P
< 0.001.
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For some viruses, the requirement for GAGs for infection of cells in culture is a
trait acquired during in vitro passaging, often leading to attenuation (34–36). To
determine whether this was the case with RVFV, we infected the B3GAT3GT and
B4GALT7GT cell panels with three pathogenic strains of RVFV: ZH-501, Kenya
9800523 (1998), and Kenya 2007002444 (2007). We found that infection by these
primary RVFV strains was also strongly inhibited in cells lacking functional GlcAT-I and
GalT-I. Infection was rescued by expression of the wild-type construct but not the
enzymatically inactive constructs (Fig. 2-2B). The dependence of primary RVFV strains
upon these enzymes indicates that the requirement of GAGs for viral infection is not due
to cell culture adaption or attenuation.
To further test the hypothesis that RVFV infection requires GAGs, we used
various GAG perturbants. The small molecule surfen binds to negatively charged GAG
species on the cell surface (37). Infection of HapI cells in the presence of surfen led to a
10-fold reduction of MP-12 infection but not vesicular stomatitis virus (VSV) infection
(Fig. 2-3A). Infection of the HapI cells by herpes simplex virus 1 (HSV-1), which is known
to utilize heparan sulfate for attachment, was decreased to levels close to background
levels by the addition of surfen. Enzymatic removal of cellular heparan sulfate with
heparinase also greatly attenuated MP-12 infection (Fig. 2-3A). Since GAGs are highly
negatively charged, nonspecific electrostatic effects could facilitate the interaction
between RVFV surface glycoproteins and cellular GAGs. To address this issue, we
infected HapI cells in the presence of dextran sulfate, a biologically inert, negatively
charged carbohydrate polymer. In contrast to HSV-1, the presence of dextran sulfate
had little impact on MP-12 infection (Fig. 2-3A), suggesting that the interaction with
cellular GAGs has some degree of specificity.
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Figure 2-3.
Perturbants of GAGs and the requirement of GAGs among
bunyaviruses. (A) GAG perturbants reduce the MP-12 infectivity of HapI cells. HapI
cells were pretreated with the small molecule surfen (5 μM), heparinase I (3 U/ml), or
dextran sulfate (50 μg/ml) and infected with MP-12, VSV, or HSV-1. The percentage of
infected cells was normalized to the percentage of infected cells treated with the vehicle
control (dimethyl sulfoxide for surfen, PBS for heparinase I, and water for dextran
sulfate). Bars indicate SEMs (n = 3). *, P < 0.005; **, P < 0.0001; ns, no significant
difference; n.t., not tested. (B) Role of GAGs for various members of the Bunyaviridae
family. B3GAT3GT and B4GALT7GT cells (see Fig. 2 legend) were infected with either
Hantaan or Andes virus pseudovirions or replication-competent CCHFV. The percentage
of infected cells was normalized to the percentage of infected wild-type cells rescued
with each protein. Bars indicate SEMs (n = 3). *, P < 0.05; **, P < 0.005; ns, no
significant difference.
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Differential requirement for GAGs among Bunyaviridae family members. To
examine whether the interaction of RVFV with GAGs was unique among bunyaviruses,
we infected the B3GAT3GT and B4GALT7GT cell panels with pathogenic, replicationcompetent Crimean-Congo hemorrhagic fever virus (CCHFV) and VSV pseudovirions
bearing the Andes or Hantaan virus glycoproteins. CCHFV is a member of the Nairovirus
genus, and both Andes and Hantaan viruses are members of the Hantavirus genus,
which are further subdivided into New World (Andes virus) and Old World (Hantaan
virus) hantaviruses (38, 39). Interestingly, Hantaan virus pseudovirions required
catalytically active GlcAT-I and GalT-I for efficient infection of HapI cells, while Andes
virus pseudovirions did not (Fig. 2-3B). Infection with CCHFV was reduced 2-fold when
B3GAT3 or B4GALT7 were absent (Fig. 2-3B). Thus, the role of GAGs during infection
by other members of the Bunyaviridae family varies.
RVFV utilizes at least one surfen-resistant cellular factor in vitro. We next sought
to characterize the role of GAGs during MP-12 infection of different cell lines using
surfen as an inhibitor of GAG function. We observed that surfen inhibited MP-12
infection in SNB-19 cells, a glioblastoma cell line, but did not inhibit MP-12 infection in
HEK 293T or mouse L cells, a mouse epithelium-derived cell line (Fig. 2-4A), or in Vero
cells (data not shown). As a positive control for surfen activity, infection by HSV-1 was
strongly inhibited in all cells (Fig. 2-4A). As an alternative means of examining GAG
utilization in L cells, we also tested MP-12 infection in sog9 cells, which are clonal
isolates of L cells that are defective in the EXT1 gene (40). EXT1 is responsible for
polymerizing disaccharide subunits from the nascent tetrasaccharide linker and was
identified in our screen as being important for RVFV infection of HapI cells (Fig. 2-1B). In
contrast to infection by HSV-1, infection by MP-12 was unaffected by the loss of GAGs
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in sog9 cells (Fig. 2-4B). To further examine the variance of this GAG-dependent
phenotype across cell types, we preincubated RVFV or HSV-1 with either heparin,
heparan sulfate, chondroitin sulfate, or dextran sulfate for 1 h prior to infection of a panel
of cell lines, including HEK 293T, A549, HeLa, Vero, and (with RVFV only) C6/36 cells,
in addition to the HapI cells. Heparin and heparan sulfate inhibited infection of both
RVFV and HSV-1 on HEK 293T, A549, HapI, and HeLa cells by at least 2-fold but not on
Vero cells, an African green monkey cell line, or of C6/36 cells, an Aedes albopictus
mosquito cell line (Fig. 2-4C). Similar results were obtained with dextran sulfate,
whereas preincubation with chondroitin sulfate had only a very modest effect on the four
human cell lines and no effect on the Vero and C6/36 cells (data not shown). Since the
composition of GAGs varies between cell types, this suggests that the GAG species that
facilitate RVFV infection may not be ubiquitously expressed. Alternatively, as is the case
with HSV-1, another entry factor may also be able to compensate for the lack of GAGs
on some cell types (41). An endocytosis-mediating receptor(s) for RVFV has not been
identified, and these data suggest that multiple entry factors are likely involved in RVFV
infection and that their relative importance may vary between cell types.
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Figure 2-4. Examination of GAG utilization by MP-12 during infection of various
cell lines. (A) MP-12 infection is resistant to surfen in some cell lines. Various cell lines
were infected with MP-12, HSV-1, and VSV in the presence of either dimethyl sulfoxide
(DMSO) or 5 μM surfen. The percentage of infected cells was normalized to the
percentage of infected cells in the dimethyl sulfoxide-treated group. (B) L and sog9 cells
were infected with MP-12, HSV-1, and VSV. The percentage of infected sog9 cells was
normalized to the percentage of infected L cells. Bars indicate SEMs (n = 3). *, P < 0.01;
**, P < 0.0001; ns, no significant difference. (C) Preincubation of HSV-1 or RVFV (MP-12
strain) with either soluble heparin or heparan sulfate prior to infection of HEK 293T,
A549, HapI, HeLa, Vero, or C6/36 cells. The concentrations listed to the right of the
graphs refer to the concentration of GAG species used during preincubation. Bars
indicate SEMs (n = 3 for all cells except C6/36 cells, for which n = 2). *, P < 0.05; **, P <
0.01; #, P < 0.001; ns, no significant difference.
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GAGs are important for RVFV entry and binding. Based on the results of the
blocking experiments with surfen and the fact that many viruses utilize GAGs for cellular
attachment, we hypothesized that GAGs facilitate efficient entry by enhancing binding of
RVFV to HapI cells. To examine this, we took advantage of the VSV pseudovirion
system that has been successfully employed for other members of the Bunyaviridae
family (16). The RVFV surface glycoproteins GN and GC are provided in trans to
replication-incompetent vesicular stomatitis virus lacking its glycoprotein (VSVΔG). To
validate the antigenic specificity of RVFV pseudovirions, we pretreated RVFV
pseudovirions with an antiserum against RVFV or the severe acute respiratory syndrome
(SARS) virus as a control. Infection by RVFV pseudovirions but not those bearing the
VSV G protein was inhibited in the presence of the RVFV antisera (Fig. 2-5A). Infection
by RVFV pseudovirions was also sensitive to lysosomotropic agents (data not shown),
consistent with the requirement for acidic endosomal pH for infection with RVFV and
other members of the Bunyaviridae family (42–45). We then infected the B3GAT3GT
and B4GALT7GT cell panels with both RVFV and VSV pseudovirions that express red
fluorescent protein (RFP). As with replication-competent RVFV, infection with RVFV
pseudovirions required catalytically active GlcAT-I and GalT-I (Fig. 2-5B). In contrast,
infection with pseudovirions bearing the VSV G protein was relatively unaffected, thus
directly implicating GAGs in RVFV entry.
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Figure 2-5. Cellular GAGs are important for RVFV entry. (A) Validation of RVFV
pseudovirions. RVFV and VSV pseudovirions were preincubated with antiserum against
either RVFV or the SARS virus before infection of Vero E6 cells. Infection values are
normalized to the viral inoculum used with untreated cells. (B) B3GAT3GT and
B4GALT7GT HapI cells that stably express the empty vector, the wild-type protein, or a
catalytically inactive point mutant were infected with either RVFV or VSV pseudovirions.
The percentage of infected cells was normalized to the percentage of infected wild-type
cells rescued with each protein. Bars indicate SEMs (n = 3). *, P < 0.01; **, P < 0.005;
ns, no significant difference.
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To measure RVFV virion binding, we employed a quantitative reverse
transcription-PCR (qRT-PCR) assay that detects RVFV L gene copies. We first
confirmed the linear range of our assay by diluting MP-12 on HapI cells and measuring
relative MP-12 binding and found that virus binding increased linearly with virus input
over a 3-log-unit range (data not shown). When this assay was applied to the
B3GAT3GT and B4GALT7GT cell panels, MP-12 binding strongly correlated with the
presence of catalytically active GlcAT-I and GalT-I (Fig. 2-6). To confirm the role of
GAGs in facilitating RVFV binding, we also measured the effect of surfen on RVFV
binding. Consistent with its role in infection, surfen also blocked RVFV binding to a
similar degree (Fig. 2-6). Taking these data together, we conclude that the deficiency in
RVFV infection in the absence of GAGs is due to a defect at the level of virion
attachment.
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Figure 2-6. Cellular GAGs are important for RVFV binding. B3GAT3GT and
B4GALT7GT HapI cells that stably express the empty vector, the wild-type protein, or a
catalytically inactive point mutant were incubated with MP-12 for 1 h at 37°C, and the
amount of cell-associated MP-12 was normalized to the number of wild-type cells
rescued with each protein. The amount of cell-associated MP-12 on wild-type HapI cells
was also measured in the presence of dimethyl sulfoxide or surfen and normalized to
that for dimethyl sulfoxide-treated samples. Bars indicate SEMs (n = 5 for HapI genetrapped mutant cells, n = 3 for surfen-treated cells). *, P < 0.05; **, P < 0.001; ns, no
significant difference.

59

PTAR1 deficiency attenuates heparan sulfate expression and confers
resistance to RVFV infection. HapI cells lacking a functional PTAR1 (14) were largely
resistant to RVFV infection, and this phenotype could be corrected by reintroduction of
wild-type PTAR1 cDNA (Fig. 2-7A), indicating that the virus resistance phenotype was
caused by the loss of PTAR1. In line with previous observations (11, 14), PTAR1deficient cells showed a marked decrease in cell surface heparan sulfate abundance, as
measured by flow cytometry (Fig. 2-7B). Similar to the virus resistance phenotype,
heparan sulfate deficiency, too, could be corrected by complementation with wild-type
PTAR1 cDNA (Fig. 2-7A and B). Considering the requirement of heparan sulfate for
RVFV infection, it seems plausible that improper presentation of heparan sulfate at the
cell surface is responsible for the observed virus resistance of PTAR1-deficient cells.
Thus, our screen has identified host factors required for RVFV infection. These factors
are involved in various steps of the heparan sulfate biosynthesis pathway and include
PTAR1, which constitutes a novel RVFV host factor affecting heparan sulfate expression
at the cell surface.
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Figure 2-7. The loss of PTAR1 renders cells resistant to RVFV infection and leads
to decreased heparan sulfate levels on the cell surface. (A) Infection of wild-type and
PTAR1 mutant (PTAR1mut) cells with MP-12. Surviving cells were visualized by crystal
violet staining. (B) Flow cytometric analysis of heparan sulfate (HS) levels, using a
specific antibody (10E4), on the surfaces of nonpermeabilized wild-type cells, PTAR1
mutant cells, and PTAR1 mutant cells complemented with either an empty vector or
PTAR1 cDNA. The percentage of cells above and below a signal threshold (horizontal
line) is indicated. In line with previous observations (11, 14), the loss of PTAR1 reduces
the levels of heparan sulfate present on the cell surface, and these levels can be
corrected by introduction of PTAR1 cDNA.
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DISCUSSION
Cell surface carbohydrates can affect virus entry at the stage of virion
attachment, but the importance of this interaction varies among viruses and cells. For
example, sialic acid is thought to be sufficient for influenza virus attachment and entry,
while the role of GAGs during HSV-1 entry is more complex (41, 46, 47). The
herpesviruses are thought to first engage heparan sulfate on the surface of cells before
engaging specific receptors (48). Heparan sulfate greatly facilitates HSV-1 attachment
and infection under many conditions but is not essential for infection in all contexts (41,
49). For example, CHO cell mutants deficient in GAG synthesis can be rendered
permissive by expressing either of the HSV-1 entry receptors nectin-1 (PVRL1) or HVEM
(TNFRSF14) (50). The expression levels of viral receptors can therefore determine
whether GAGs are required for efficient viral entry.
The cellular receptor(s) for RVFV is currently not known, and since a
nonpermissive cell line is yet to be described, it is possible that more than one molecule
may serve as a receptor for RVFV. The C-type lectin DC-SIGN has been shown to
promote the binding and internalization of RVFV on dermal dendritic cells, although this
protein is not expressed in most of the tissues which the virus has been shown to infect
(51). A genome-wide RNA interference screen performed by Hopkins and colleagues did
not identify glycosaminoglycans among their list of genes that impacted RVFV infection
(52). We have shown that several perturbations of GAGs inhibited RVFV entry and
attachment on some cell types, but the relative contribution of other RVFV entry factors
remains unknown. Because we observed differential sensitivities of RVFV to surfen, it is
possible that the requirement for GAGs across cell types is a function of the relative
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expression levels of an uncharacterized RVFV receptor(s), GAG structures to which
surfen binds inefficiently, or unidentified attachment factors. Indeed, the composition of
cellular GAGs between cells is highly variable (53). While heparan sulfate is the beststudied variant, there are at least four other species, each consisting of a unique
disaccharide unit. Several enzymes are involved in modifying the different glycan side
chains following polymerization. For example, HSV-1 interacts with 3-O-sulfated heparan
sulfate, which is catalyzed by the 3-O-sulfotransferase family of enzymes (49). Our data
suggest that RVFV may require a specific enzymatic variant of a GAG species or cellular
proteoglycan. Further work is needed to elucidate the role of specific GAG-modifying
enzymes and cellular glycoproteins during RVFV infection.
Heparan sulfate has previously been implicated as playing a role in RVFV
infection. A study by de Boer et al. employed a replication-incompetent virus-like particle
(VLP) system and found that CHO cells with genetic deficiencies in GAG synthesis were
highly resistant, though not immune, to RVFV infection (13). This is in line with our
observation that HapI cells incapable of producing GAGs are approximately 10-fold more
refractory to RVFV infection than their parental (wild-type) HapI cells. Infection by
Toscana virus, another member of the genus Phlebovirus of the family Bunyaviridae,
has been shown to be inhibited by bovine lactoferrin through competition for GAGs on
the cell surface (54). These results and our finding that the importance of GAGs and
heparan sulfate for RVFV infection exhibited cell type dependence suggest that these
molecules serve as virus attachment factors that can enhance but that are not absolutely
required for virus infection and therefore do not represent indispensable viral receptors.
By employing RVFV-VSVΔG pseudovirions and an RVFV binding assay, we
definitively linked GAGs to RVFV entry and, more specifically, to virus binding. It remains
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to be determined whether the impact of heparan sulfate on RVFV infection of some cell
types reflects the inefficiencies of cell-free virus attachment in vitro or whether these
interactions are important in vivo as well, though the fact that primary RVFV strains
behaved similarly to the MP-12 vaccine strain shows that these interactions are not the
result of in vitro virus adaptation. Interestingly, the tissue tropism of adeno-associated
virus 2 (AAV2) to the liver and kidney, organs in which RVFV also establishes productive
infection, is exquisitely linked to interactions with GAGs (55–58). Infections with RVFV in
pregnant livestock are devastating, and pathological studies of infected pregnant
livestock reported extremely high virus titers in the placenta, an organ whose cells
express high levels of surface GAGs (59, 60). Interactions with placental GAGs may
explain the mechanism by which RVFV localizes to the placenta from the bloodstream.
The haploid genetic screen utilized here identified multiple genes involved in
GAG synthesis or transport, including PTAR1. Whereas we cannot formally exclude the
possibility that PTAR1 affects virus susceptibility by other means, it is most likely also
involved in mediating GAG-dependent viral entry. Cells deficient for PTAR1 displayed
decreased levels of heparan sulfate at their cell surface, which is in agreement with the
observations obtained with cells with PTAR1 mutations in previous genetic screens (11,
14). Additional experiments examining the precise role of PTAR1 in heparan sulfate
biogenesis and trafficking are needed to shed light on the mechanism of PTAR1dependent RVFV infection. Finally, the ability of this screening approach to identify
additional host factors that are important for RVFV infection may be enhanced by
employing cell types where virus attachment occurs in a GAG-independent manner.
The interaction of primary pathogenic RVFV isolates with GAGs suggests that
this interaction might be an attractive pharmacological target in humans or other
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animals. Heparan sulfate has indeed been shown to be important in human
papillomavirus infection of mouse female genital tracts (61), and administering antiheparan sulfate peptides as a prophylactic eye drop was shown to inhibit the spread of
HSV-1 in the mouse cornea (62, 63). Although we need to further characterize the exact
role of GAGs during RVFV infection in vitro and in vivo, our current study suggests that
disruption of virus-GAG interactions could be a viable antiviral therapy or prophylactic
measure.
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CHAPTER 3: THE WASH COMPLEX IS REQUIRED FOR
INTOXICATION OF CLOSTRIDIUM DIFFICILE TOXIN B

ABSTRACT
Clostridium difficile infection causes a severe diarrheal disease that is increasing
in incidence and becoming more resistant to treatment. Its secreted virulence factor
Toxin B (TcdB) is internalized into host cells, where it inactivates Rho GTPases and
causes significant cytotoxicity.

The host factors supporting TcdB internalization and

transport are largely unknown. We report here a forward genetic screen in human
haploid cells that identified the Wiskott–Aldrich syndrome protein and SCAR homologue
(WASH) complex as a host cellular factor supporting TcdB intoxication. The involvement
of the WASH complex in TcdB entry was validated by pharmacologic inhibition of
recycling endosomes and the use of mouse fibroblasts lacking a functional WASH
complex due to genetic ablation of the core WASH1 gene. Our data help to elucidate
the mechanism of intoxication of this important and poorly-characterized virulence factor.
INTRODUCTION
The anaerobic bacterium Clostridium difficile causes severe antibiotic- and
hospital-associated diarrhea and pseudomembranous colitis. C. difficile infection can
lead to septic shock, perforation of the intestine, and toxic megacolon, and is fatal for
about 9% of patients (1). In the United States, the CDC estimates 500,000 cases of C.
difficile infection annually (2) and rates of C. difficile colitis have been increasing: from
2005 to 2010 there was a 47% increase compared to the five years prior (3). Spore
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formation by the bacterium and worsening resistance to treatment have hindered
sterilization, prevention, and treatment efforts.
C. difficile secretes two large multidomain toxins, TcdA and TcdB, that are the
virulence factors primarily responsible for its pathogenesis. TcdB has been shown to be
approximately 100-1000 times more cytotoxic than TcdA, and is believed to cause most
of the severe disease symptoms associated with C. difficile infection (4-6). TcdB is 270
kDa and comprises the following domains: a glucosyltransferase domain (GTD) located
at the N-terminus of the protein, a cysteine protease domain (CPD) responsible for autocleavage, a translocation domain (TMD) that includes a pore-forming region (PFR), a
receptor binding domain (RBD) containing a combined repeat oligopeptides (CROP)
region involved in binding and attachment at the cell surface, and newly-identified
secondary RBD adjacent to the first. See Figure 3-1A for a schematic of the TcdB
domain organization.
After binding to the cell surface via either of the RBDs, the toxin is internalized
into an endosome. Acidification of endosomes is thought to induce a conformational
change in the toxin, leading to pore formation and translocation of the CPD and GTD
into the cytosol (7). The CPD then cleaves the GTD, freeing it to interact with its target
Rho GTPases in the cytosol. TcdB has been shown specifically to glucosylate RhoA,
Rac1, and Cdc42, although this varies by bacterial strain (8). Glucosylation of these
Rho GTPases disrupts the numerous cell processes that they control, including cell
polarity, vesicle trafficking, and microtubule and actin cytoskeletal regulation. It is this
inactivation of the Rho GTPases that are thought to be responsible for the cytotoxic
effects of TcdB. The current model of the TcdB intoxication is shown in Figure 3-1B.
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Recent studies have demonstrated that chondroitin sulfate proteoglycan 4
(CSPG4) and Frizzled proteins can act as non-competitive receptors for TcdB but that
their relative contributions to toxin entry depend upon their cell-type-specific expression
levels (9,10). The host factors involved in the remaining entry steps of the toxin have not
been well characterized. TcdB entry was shown to be blocked by pre-treatment with
dynasore or chlorpromazine, but not by expression of plasmids encoding dominantnegative Cav-1 or Eps15, indicating that toxin entry is both dynamin- and clathrindependent (11). The endocytic route utilized by TcdB as it traffics within the cell, its site
of translocation, and the host factors upon which it relies during these processes have
yet to be described.
To identify host factors required for intoxication by TcdB, we have employed an
unbiased forward genetic screening strategy using human haploid cells. We report here
a role for the Wiskott–Aldrich syndrome protein and SCAR homologue (WASH) complex,
which mediates membrane-cytoskeleton interactions and is important for cargo sorting at
endosomes, in the entry of TcdB toxin. These data help to elucidate the mechanisms of
intracellular transport of TcdB in mammalian cells.
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Figure 3-1. TcdB entry and structure. (A) The structure of TcdB toxin. GTD:
glucosyltransferase domain, CPD: cysteine protease domain, PFR: pore-forming region,
TMD: translocation domain, RBD: receptor binding domain, CROPs: combined repetitive
oligopeptides. (B) The intoxication process of TcdB: binding at the cell surface (1) is
followed by receptor-mediated endocytosis (2). Acidification of the endosome induces a
conformational change in the toxin that results in formation of a pore (3). Autocatalytic
cleavage and release of the GTD (4) leads to glucosylation of Rho GTPases (5) which
are thereby inactivated.
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MATERIALS AND METHODS
Haploid mutant library generation and screening. Approximately 1x109 HAP1
cells were mutagenized as previously described (12). Briefly, HAP1 cells were enriched
for haploid status and then mutagenized with a retroviral pLentiET gene trap virus.
Parental (WT) HAP1 cells (3x106 cells total) and the mutant library (8x107 cells total)
were challenged in parallel with TcdB at a concentration of 0.5 nM. Three sequential
toxin selections were performed. After the first and second selections, surviving cells
were allowed to expand for approximately 8 days before being trypsinized and reseeded at 30% confluency prior to subsequent challenge. After the third selection, all
WT HAP1 cells were dead, and the surviving cells from the mutant library were allowed
to recover for 10 days and then pooled for genomic DNA isolation.
Integration site mapping. DNA from the mutant library as well as the TcdBselected population was isolated and gene trap insertion – host junction sites were
amplified and then submitted for sequencing on either 454 or Illumina platforms, followed
by alignment to the human genome (hg18). Significance of enrichment of the integration
sites identified within the TcdB-selected pool relative to the unselected library was
calculated using one-sided Fisher’s exact test.
Cell culture. WASH1flox/flox and WASH1-/- mouse embryonic fibroblasts (MEFs)
were a kind gift from Dan Billadeau (Mayo Clinic) and were generated as described in
(13). Vero C1008 cells and HeLa cells were obtained from ATCC. All cell lines were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented by 10% fetal
bovine serum (FBS).
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Reagents and antibodies.

Toxin B (TcdB) from Clostridium difficile was

purchased from List Biological Laboratories, catalog number 155L. Primaquine was
purchased from Sigma-Aldrich, catalog number 160393. The following antibodies were
used: chicken anti-TcdB (List Biological Laboratories 754A), mouse anti-Rac1 clone
23A8 (EMD Millipore 05-389), mouse anti-Rac1 clone 102 (BD Biosciences 610650),
rabbit anti-FAM21C (Abcam 184131), rabbit anti-EEA1 (Cell Signaling Technology
2411S), rabbit anti-LRP1 (Abcam 92544), rabbit anti-CSPG4 (Abcam 139406), and
rabbit anti-FZD7 (Abcam ab51049).
Cell-rounding assay. Cells were plated at 25% confluency 15-20 hr prior to
treatment with TcdB. Toxin was diluted in DMEM + 10% FBS and applied to cells at the
indicated concentrations. After 6 hours, cells were imaged on a Nikon Eclipse TE300
inverted microscope and scored by visualization of rounded cells (minimum of 100 cells
per image). Percent cell rounding was calculated for each sample as follows: [(number
rounded cells / number of total cells analyzed) * 100].
Immunoblotting. Cells were trypsinized and cell pellets were rinsed with PBS,
flash frozen, and then resuspended in 2X lysis buffer (0.1M Tris with 20% glycerol and
5% SDS). Lysates were heated at 95°C for 5 min, passed through a 28-guage needle 3
times, heated again at 95°C for 5 min, and total protein was quantified using the Pierce
BCA Protein Assay Kit. Samples were run through 4-12% Bis-Tris gradient gels at 100V
in 1X MES buffer, and then transferred to PVDF membranes using the iBlot 2 Dry
Blotting System.

Membranes were blocked in a milk solution for 1 hr at room

temperature and then probed with primary antibodies (diluted in blocking buffer)
overnight at 4°C.

Membranes were then washed and probed with HRP-conjugated

secondary antibodies.

HRP was detected using SuperSignal West Pico or Femto
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Chemiluminiscent Substrate (Fisher Scientific 34095 or 34080) and developed on the
GE Amersham Imager 600.
RESULTS
An insertional mutagenesis screen in human haploid cells identifies host
cell factors required for TcdB toxin.

To identify host factors used by TcdB, we

employed an unbiased forward genetic screening strategy in the human haploid cell line
HAP1, which was derived from KBM7 cells (14). Approximately one billion HAP1 cells
were mutagenized with a lentiviral gene trap vector to generate a library of loss-offunction clones harboring inactivating viral insertions. This library, as well as parental
(unmutagenized) HAP1 cells, was thrice challenged with TcdB toxin at 0.5 nM
concentration. After the third challenge, there were no surviving cells within the parental
population, and the surviving clones from the mutant library were pooled for DNA
sequencing and mapping of the lentiviral integration sites. A profile of insertion sites
within the selected population was determined and compared to that of the original
mutant library.

We determined the integration-site containing genes that were

significantly (p value < 0.05) enriched within the selected cells relative to the library to
yield a hit list of genes whose disruption confers a resistance phenotype, as shown in
Figure 3-2.
Among these hits, we identified LDL receptor related protein 1 (LRP1), which
was recently reported to be a receptor for the Clostridium perfringens toxin TpeL, a
closely-related clostridial glycosylating toxin that lacks the CROPs region (15). The
authors examined the entry of CROP-deficient truncated C. difficile TcdB toxin into
MEFs that lack LRP1, and saw no difference compared to parental (wild-type) MEFs, so
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there has not yet been any evidence that LRP1 acts as either a receptor or attachment
factor for TcdB, although this may depend on cell type. We also identified WASHC5
(KIAA1096) and WASHC4 (KIAA1033), which encode the proteins Strumpellin (also
called WASHC5) and Strumpellin and WASH-interacting protein (SWIP, also called
WASHC4), two of the five core members of the WASH complex. Additional hits included
COMMD8, COMMD10, C16orf62, and CCDC63, all of which encode members of the
COMMD/CCDC22/CCDC93 (CCC) complex, a recently-identified multisubunit protein
complex that interacts with the WASH complex and participates in cargo transport at
endosomes (16). The screening hits also included multiple genes encoding proteins that
have established or putative roles in membrane trafficking and endocytosis.
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Figure 3-2. Human haploid screen for TcdB host factors. Genes whose disruption
was significantly enriched (p value > 0.05 indicated by red line) in the TcdB-selected
population relative to the unselected mutant library. Each circle denotes a gene, with yaxis position showing the false discovery rate-corrected p value, and distribution along
the x-axis corresponding to chromosomal position. Circle colors indicate genes
encoding members of the Wiskott–Aldrich syndrome protein and SCAR homologue
(WASH) complex, the COMMD/CCDC22/CCDC93 (CCC) complex, or the function of the
gene product.
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Because our screen identified multiple members of the WASH complex as well
as the interacting CCC complex, and because the host machinery required for transport
of TcdB through the cellular endocytic pathway has not been well described, we decided
to investigate the involvement of the WASH complex in TcdB entry. The WASH complex
is a Type I nucleation-promoting factor that has been shown to interact with the retromer
cargo-selective complex (CSC) at the endosomal membrane, where it activates the
Arp2/3 complex in order to drive formation of branched actin patches that define
microdomains of the tubular endosomal network. These actin patches are critical for
cargo transport back to the plasma membrane as well as to the Golgi apparatus, and
may also play a role in signaling processes [reviewed in (17)].
TcdB cytotoxicity is blocked by inhibition of recycling endosomes.

An

important role for the WASH complex has been defined during the process of
endosome-to-cell surface recycling. Driven by its association with the retromer CSC and
sorting nexin 27 (SNX27), the WASH complex can be recruited to sites of cargo that
contain a PDZ domain-interacting motif, where its actin patch-forming activity is required
for the recycling of these cargoes, such as β2 adrenergic receptors, from EEA1-positive
endosomes back to the plasma membrane (18).

We therefore used the recycling

inhibitor primaquine to interrogate the involvement of this pathway during TcdB
intoxication.

Primaquine has been shown to interfere with the function of recycling

endosomes in a manner that is independent of pH neutralization or osmotic swelling
(19).
Vero cells (derived from African green monkey kidney) or HeLa cells were plated
at approximately 25% confluency and then pre-treated for one hour with 100 uM
primaquine prior to addition of TcdB toxin at 0.2 or 0.8 pM, or a vehicle control of
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equivolumetric DMSO.

Cell rounding was scored (at six hours post intoxication) as a

read-out for TcdB activity. Figures 3-3A and 3-3B show the imaging and quantification,
respectively, for primaquine’s inhibition of TcdB-induced rounding in Vero cells, and
Figures 3-3C and 3-3D show the same for HeLa cells. In both cell lines, pre-treatment
with primaquine greatly decreased the cell-rounding phenotype, though this effect was
more pronounced in the Vero cells, perhaps due to the fact that they are more sensitive
to the effect of toxin (nearly all Vero cells rounded with treatment of 0.8 pM TcdB,
compared to ~ 50% rounding of HeLa cells at the same concentration; Fig. 3-3C versus
3-3D). This supports a role for recycling endosomes in the trafficking of TcdB toxin.
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Figure 3-3. Primaquine treatment blocks cytotoxicity of TcdB toxin. Vero cells
(A,B) and HeLa cells (C,D) were pre-treated with primaquine and then intoxicated with
TcdB for six hours at the indicated concentrations. Brightfield imaging of treated cells
(A,C) and quantification of cell rounding (B,D). Shown are representative images for
selected concentrations; a minimum of 100 cells per sample were imaged and
quantified; N=2 independent experiments.
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The WASH complex is required for TcdB cytotoxicity. To more directly test
the involvement of the WASH complex in TcdB entry, we utilized WASH1-/- mouse
embryonic fibroblasts (MEFs) bearing a deletion within the WASH1 gene that results in
dysfunction of the entire WASH complex (13). In these WASH1-/- MEFs, the central
WASH1 component of the complex (see Figure 3-4A) is depleted and expression of the
other subunits is greatly decreased, leading to trafficking defects and a collapsed
endosomal network (13).
We first sought to characterize the cell surface expression of proteins that might
be involved in TcdB binding and attachment, to see whether changes in their levels
might account for the decreased toxin entry. As the WASH complex is required for
recycling of many proteins to the cell surface, it was possible that this type of indirect
effect may have been responsible for the resistance phenotype of WASH-deficient
clones in our screen, rather than a direct impact on toxin intracellular trafficking. We
stained non-permeabilized cells with antibodies raised against CSPG4 and FZD7, two
proteins that have been shown to act as receptors for TcdB in some cell types (9,10).
Fluorescence staining profiles of the WASH1-/- and WASH1flox/flox MEFs, shown in
Figure 3-4B, show no obvious differences in expression of CSPG4 between the cell
lines.

Cell surface presentation of FZD7 and LRP1 was slightly increased in the

WASH1-/- MEFs, indicating that these potential receptor or attachment factors are still
present at the cell surface in this WASH-deficient cell line.
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Figure 3-4. Characterization of WASH-deficient fibroblasts. (A) The WASH
complex shown with its key interacting partners and adaptor proteins at the tubular
endosomal network.
WASH complex components: Strumpellin, SWIP, WASH1,
CCDC53, and FAM21 (also called VPEF). Interacting partners and adaptor proteins: the
retromer cargo-selective complex (CSC) comprising VPS26, VPS29, and VPS35, which
mediates cargo selection; RME-8 (also called DNAJC13) that coordinates association of
the WASH complex with the retromer sorting nexin (Snx-BAR) dimer; FKBP15 (also
called WAFL), which interacts with the FAM21 tail; SNX27 that helps direct this
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machinery to recycle its PDZ domain-interacting cargo via interaction with the CSC and
FAM21; the COMMD/CCDC22/CCDC93 (CCC) complex, which is involved in
endosomal sorting and interacts with FAM21; and the heterodimer capping protein (CP,
also called CapZ) that caps the barbed ends of actin filaments. (B) Cell surface staining
of WASH1flox/flox and WASH1-/- MEFs.
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We then tested the susceptibility of the WASH1flox/flox and WASH1-/- MEFs to
TcdB intoxication. The WASH1flox/flox and WASH1-/- cells were plated at approximately
25% confluency 15-20 hours prior to intoxication and then TcdB (at 0, 0.2, 0.4, 0.8, and
1.6 pM) or DMSO (as an equivolumentric vehicle control) was applied to the cells for 6
hours. The cells were then imaged (Figure 3-5A) and quantified for cell rounding (Figure
3-5B).

Cytotoxicity of the toxin was decreased in the WASH-deficient MEFs

approximately 2-fold, though not completely blocked.

This resistance phenotype

supports a role for the WASH complex in the entry of TcdB toxin into mammalian cells.
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Figure 3-5. Cell-rounding of TcdB-treated WASHflox/flox and WASH-/- fibroblasts. (A)
Representative images of cell-rounding activity of TcdB on WASHflox/flox and WASH-/MEFs at selected concentrations. (B) Quantification of the percent cells rounded. A
minimum of 100 cells per sample were imaged and quantified; N=2 independent
experiments.
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Rac1 glycosylation by TcdB in the absence of a functional WASH complex.
To further probe the involvement of the WASH complex in TcdB intoxication, we treated
WASHflox/flox and WASH-/- MEFs with the toxin and then lysed cells after 30 or 45 minutes
of toxin treatment in order to examine the kinetics of TcdB glucosylation of its target
GTPase Rac1. We took advantage of two mouse antibodies against Rac1: clone 102,
which detects only non-glysocylated Rac1 protein, and clone 23A8, which detects both
glycosylated and non-glycosylated Rac1 protein. Whole cell lysates were separated by
SDS-PAGE gel electrophoresis, transferred to PVDF membranes, and then probed with
the aforementioned antibodies. Western blots of these two timepoints are shown in
Figure 3-6A and 3-6B. The gel analysis tool of ImageJ was used to quantify the density
of bands and we then calculated the fraction of non-glycosylated Rac1 for each sample
as [density of the band detected by the clone 102 antibody) / (density of band detected
by clone 23A8 antibody)] and this fraction (normalized to untreated cells) is plotted in
Figure 3-6C and 3-6D.
After 30 minutes of TcdB treatment at the lower concentration, the majority of
cellular Rac1 in both the WASHflox/flox and the WASH-/- MEFs was still non-glycosylated,
with a greater degree of Rac1 glycosylation by 0.02 pM TcdB than 0.005 pM, but levels
were comparable between the WASH-deficient cells and the control cells.

After 60

minutes of TcdB treatment, both concentrations of toxin we tested produced significantly
more glycosylation of Rac1 compared to the 30-minute treatment. The degree of Rac1
glycosylation in the WASHflox/flox MEFs was slightly greater than that of the WASH-/MEFs at this timepoint, but the phenotypic effect of WASH-deficiency was more modest
than that observed with the cell-rounding assay. Interestingly, the concentrations of
toxin we used for this assay (both of which were able to glycosylate significant fractions
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of cellular Rac1 by 60 minutes) were equal to or less than 0.02 pM, a concentration of
toxin which was only able to produce a cell-rounding phenotype in fewer than 20% of
cells for both WASH-deficient and control MEFs. These data therefore indicate that
glycosylation of Rac1 cannot necessarily be used as a read-out for the full spectrum of
cytotoxic activity of the toxin, and that the WASH complex may be required during a
stage of TcdB intoxication that only slightly impacts its ability to glycosylate Rac1.
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Figure 3-6. Western blot analysis of Rac1 glycosylation by TcdB in WASH1flox/flox
and WASH1-/- fibroblasts. WASH1flox/flox and WASH1-/- MEFs were treated with TcdB
for either 30 minutes (A,C) or 60 minutes (B,D) after which cells were lysed and
subjected to immunoblot against either non-glycosylated Rac1 (using anti-Rac1 clone
102) or total Rac1 (using anti-Rac1 clone 23A8). Western blots (including a loading
control, alpha-tubulin) are shown in (A) and (B) and quantification of the above Western
blots (done in ImageJ) are shown in (C) and (D).
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DISCUSSION
We report here a forward genetic screen in human haploid cells that identifies
host factors involved in TcdB intoxication. These screening hits were enriched for genes
encoding proteins involved in endocytosis and membrane trafficking, in particular the
WASH complex and its interacting partner the CCC complex. We pharmacologically
inhibited endosomal recycling to show that this process is required for TcdB intoxication
of mammalian cells, and used WASH-deficient fibroblasts to show that TcdB cytotoxicity
is diminished in the absense of a functional WASH complex. These fibroblast cell lines
also showed a modest decrease in levels of glycosylation of Rac1, a target GTPase of
TcdB toxin when it enters the cytoplasm, although the concentration of TcdB required to
glycosylate the majority of cellular Rac1 was much lower than the concentration required
to induce a cell-rounding phenotype in the majority of cells.
Since its initial characterization less than a decade ago, the WASH complex has
emerged as a key regulator of multiple aspects of cargo sorting and membrane
trafficking at endosomes (20,21). There are several possible ways in which the WASH
complex may function to support TcdB intoxication. Its nucleation of actin branching at
the tubular endosomal network has been shown to be involved in cargo recycling to the
plasma membrane, as well as to the trans-Golgi network (TGN), depending upon its
interactions with adapter proteins, particularly sorting nexins (18, 21-23). A role for the
WASH complex has also been demonstrated in the maturation of endosomes and
delivery of cargo to lysosomes (24). As the endocytic route used by TcdB toxin has not
been fully characterized, it is possible that the WASH complex could be supporting TcdB
entry at any of the aforementioned locations.
92

Elucidation of the endosomal

compartments through which TcdB traffics will help to inform our understanding of its
potential reliance upon the WASH complex.
Other hits from our screen are also suggestive of the involvement of particular
arms of the host endocytic machinery in TcdB entry and therefore warrant investigation.
SNX17, for example, has been shown to be important for cargo to escape a lysosomal
fate, although the authors found that it did not co-precipitate WASH complex proteins
(25).

HOOK2 is a relatively uncharacterized microtubule-binding protein that’s been

shown to recruit cargo to the centrosome (26).

We also did not directly test the

involvement of the CCC complex, which interacts with the WASH complex and has been
shown to regulate recycling of Notch, LDLR, and the copper transporter ATP7A (16, 27,
28). It would be very interesting to see whether the CCC complex may be acting to
support TcdB entry in a manner that is either independent of its established partnership
with the WASH complex, or whether it is able to partially rescue the trafficking defect that
results from WASH complex dysfunction.
Our screen also identified the gene FBXO11, which encodes a member of the Fbox protein family that interacts with the TGFβ signalling pathway. This gene was the
top hit in the recent CRISPR screen that identified Frizzled proteins as TcdB receptors
(10), suggesting quite strongly that it may be required for TcdB intoxication. One of our
top hits was the gene LRP1, which encodes a receptor for the closely-related clostridial
toxin TpeL. Although the authors concluded that LRP1 did not play a role in CROP-less
TcdB entry, it may be worthwhile to re-examine the possibility that LRP1 supports TcdB
entry in some way. Since the use of CSPG4 and Frizzled proteins as receptors for TcdB
has been shown to depend upon the relative expression levels of these proteins at the
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cell surface, it is certainly possible that LRP1 facilitates entry of TcdB in our screening
cell line, HAP1, and not in the MEFs used by Schorch, et al. (15).
Together, our data indicate a novel role for the WASH complex in the intoxication
of mammalian cells by the C. difficile virulence factor TcdB. This sheds light on the array
of host cellular factors that are utilized by the toxin as it enters and traffics through the
cell, and it furthers our understanding of the function of this recently-characterized
nucleation-promoting machinery. Future work is needed to define the precise endocytic
compartments occupied by TcdB within the cell, and to characterize the mechanism by
which the host’s cargo trafficking infrastructure interacts with and supports the entry of
this clinically important toxin.
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CHAPTER 4: DISCUSSION AND FUTURE PERSPECTIVES

THE COMPLEMENTARITY OF DIVERSE SCREENING APPROACHES
High-throughput

loss-of-function

screening

techniques

have

provided

tremendous insights into host-pathogen interactions, and one of the most widely-used
and efficacious of these has been the stalwart RNAi screening approach. RNAi screens
have been performed in a wide range of cell lines, spanning multiple species, and have
interrogated aspects of cell biology as diverse as organelle morphology and
mechanisms of resistance to drug toxicity [reviewed in (1)]. As RNAi screening became
more popular, though, it also became evident that the technology suffered from issues of
reproducibility and a high rate of false discovery. Results of the three genome-wide
siRNA screens performed with HIV in 2008 (2–4), each of which had generated a list of
approximately 300 genes supporting HIV infection in 293T or HeLa-derived cells, were
subjected to in-depth meta-analysis by Bushman and colleagues in 2009, who reported
that the percentage of overlap in gene hits between any two of the three screens was
6% at most (5). Two genome-wide RNAi screens were performed in 2009 to uncover
host factors required for hepatitis C virus (HCV) replication in human cells. Tai et al. (6),
using an HCV subgenomic replicon, reported the identification of 96 genes that support
HCV replication, and Li et al. (7), using infectious virus, then identified 262 genes
impacting infection, only 15 of which overlapped with the previous screen’s findings. In
the last five years, two genome-wide RNAi screens using Sindbis virus (SINV) have
been performed, one in Drosophila cells (8, 9), and one in human cells (10). The screen
in Drosophila cells identified 57 genes supporting and 37 genes that restricted SINV
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infection, while the screen in human cells identified 56 genes supporting and 62 genes
restricting infection – but there was very little overlap between the genes identified
[compare (10) Tables S2 and S3 with human homologues of (9) Table S1].
Much of the reason for this lack of overlap between seemingly similar RNAi
screens has been ascribed to the off-target effects of siRNAs and differences between
technical aspects of the screening conditions. In a recent analysis of three genome-wide
RNAi screens (one with UUKV and two with bacterial pathogens), Franceschini and
colleagues concluded that the phenotypic effects of siRNA oligos were in fact
predominantly due to off-target microRNA activity conferred by the seed region
sequence, rather than the intended siRNA activity (11). They found significantly higher
phenotypic correlations when siRNA oligos from different vendors were grouped by seed
sequence (nucleotides 2-8) than when they were grouped by intended target (full-length
complementarity of all 21 nucleotides).

The authors confirmed these findings by

designing custom oligos containing seed sequences predicted to impact infection that
were flanked by arbitrary sequences outside of the seed region, and demonstrated that
overexpression of known human microRNAs phenocopied the effect of siRNA oligos
with corresponding seed sequences. These findings beg a reexamination of the raw
data that have been generated by previous RNAi screens, as well as an attentive
consideration of microRNA effects during analysis of any future screens. In addition to
the off-target activities of the oligos themselves (which can cause both false positive and
negative results), differing gene expression levels between cell types, variable
efficiencies of transfection protocols, and discordance between knockdown timing and
the half-life of the target protein can all contribute to a high false-negative rate. Recent
improvements in both design and analysis of RNAi screens have sought to address
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these problems, such as the Minimum Information About an RNAi Experiment (MIARE)
reporting guidelines (http://miare.sourceforge.net) that have been established, and the
utilization of the multiple orthologous RNAi reagents coupled with RNAi gene enrichment
ranking (MORR-RIGER) method, which helps to reduce false negatives and filter offtarget effects (12). For a detailed discussion about the factors impacting RNAi screen
success, recent technical updates, and current design and analysis strategies, see
reference (1) and the references therein.
Like RNAi, haploid screening is a forward genetic approach, allowing for
discovery of novel host factors in the absence of a presumed or suspected mechanism
of action.

Although the technique is relatively new and comparatively few studies

employing this approach to study virus-host interactions have been published, it is clear
that haploid screening offers some important advantages over RNAi screening.

A

significant advantage is the fact that the insertional mutagenesis strategy employed to
generate the haploid libraries usually results in complete disruption of the gene product,
rather than the transient partial depletion that results from RNAi targeting. This in turn
greatly increases the signal-to-noise ratio of the data that are obtained. Generation of
many independent mutants within the library that each bear separate integrations into
the same gene locus also allows for rigorous statistical analysis to identify genes whose
absence was selected for within the surviving mutant pool. The fact that this selection is
occurring in a cell line of human origin is also attractive because it increases the
likelihood of finding biologically meaningful factors that participate in the host-pathogen
interaction during the course of human disease.
It may be premature to attempt to evaluate the reproducibility of haploid genetic
screens as published applications of this screening technique have utilized a diverse
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array of pathogens, including Ebola virus, Lassa virus, RVFV, enterovirus D68, and
adeno-associated virus serotype 2 (13–18). Diphtheria and anthrax toxins, Clostridium
perfringens TpeL toxin, Pseudomonas aeruginosa exotoxin A, and Staphylococcus
aureus α-toxin (19–22) have also been investigated with this approach.

To our

knowledge, ANDV is the only selective agent to have been used in two completely
independent haploid genetic screens performed by different labs. The degree of overlap
between these two screens, however, was striking. In the 2014 study by Petersen and
colleagues, four genes encoding members of the sterol regulatory pathway (SREBF2,
S1P, S2P, and SCAP) were enriched for disrupting integrations well above any other
genes (23) and the 2015 screen performed by Kleinfelter et al. reported that these exact
same four genes were also their top hits, and that three other genes involved in
cholesterol biosynthesis (LSS, SQLE, and ACAT2) were the next most frequently
disrupted (24). This identification of multiple members of a biological pathway has been
seen in many of the aforementioned haploid screens, and it not only demonstrates the
high level of mutagenesis coverage in the libraries that have been generated thus far,
but it also increases the confidence that screening hits are biologically relevant.
The haploid screening technique is not without drawbacks. Due to the nature of
disrupting mutagenesis in a haploid genetic background, this screening strategy is
unlikely to identify host factors that are required for cell viability.

Additionally, most

haploid screens have relied upon cell death as a phenotypic read-out, a decision that
greatly increases the throughput of the screen but that may prevent the identification of a
gene whose disruption produces an intermediate phenotype in which virus infection is
delayed or partially suppressed. We find it interesting that in a number of the published
screens a single biological pathway is clearly identified by virtue of multiple retroviral
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gene insertions to the near exclusion of other hits. In the two Andes virus haploid
screens (23, 24), cells that survived the viral challenge almost invariably had one of
several genes involved in cholesterol biosynthesis disrupted, and in the RVFV haploid
cell screen we performed, genes contributing to glycosaminoglycan synthesis and Golgi
complex function were mutated in the surviving pool almost to the exclusion of any other
mutations. In contrast, RNAi screens often implicate several biological pathways as
being important for viral replication, as did the RVFV RNAi screen published by Hopkins
et al. Variables that could impact the results of haploid cell screens could include the
multiplicity and timing of infection as well as the length of time cells are cultured after
virus challenge. Finally, most haploid screens have utilized mutant libraries generated in
the human haploid cells HAP1, a line derived from the KBM-7 chronic myeloid leukemia
cell line, which restricts its use to pathogens that are capable of entering these cells, as
well as introducing an element of complexity due to cell-type-specific variations that have
been observed in entry mechanisms and pathway use of viruses and toxins.
Interrogating host-pathogen protein-protein interactions through Y2H, AP/MS, or
proximity labeling makes it possible to identify host factors based upon the a priori
association of a pathogen protein and a cellular protein within the biological context of
the host cellular environment. Many of the common phenotypic read-outs used during
viral screening techniques, such as production of a reporter protein or host cell death,
have the distinct disadvantage of restricting host factor discovery to those which impact
a specific subset of stages during the viral replication cycle. High-throughput screens to
identify cellular factors required for viral assembly and egress, for example, have proven
difficult to design, and screens to identify host factors required for viral infections have
largely focused on the rate-limiting stages of entry and replication. Another important
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advantage to protein-protein interaction screening is that it allows for the identification of
host factors whose depletion or disruption may be cytotoxic, or even lethal. On the other
hand, antibodies to affinity purify a pathogen protein are not always available, and the
introduction of a tag or the precipitation conditions may perturb protein function or have
other unforeseen consequences.
The use of multiple complementary screening techniques can serve to address
and overcome the varying advantages and disadvantages presented by using each of
the techniques on their own. Performing multiple screens in parallel can help eliminate
false-positive hits, even if the differences between the screens are relatively subtle
technical changes such as use of different viral strains, cell types, or siRNA libraries.
With each new published screen, the pool of datasets available to draw from also
increases, which will allow for valuable comparisons of one’s screening results with the
reported hits from other related screens.
HAPLOID GENETIC SCREENING: LESSONS LEARNED
Many factors influence the outcome of haploid screens, and during the projects
described here, as well as other screens done in our lab or in collaboration with the
Bates lab, I have learned some lessons about the design of these screens.

The

generation of the mutant library is the first point of strategy, as care should be taken to
limit expansion of the cells after lentiviral mutagenesis.

The reason for this is that

mutations introduced by this process can have dramatic effects on the growth rate of the
cells, and this leads to an outgrowth of fast-growing mutants and a loss of slow-growing
mutants.
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Another factor that greatly impacts screen design is the nature of the selective
agent being used to challenge the library. I have used toxins, pseudoviruses, and live
viruses for screening, and different screening strategies are required for each. Toxins
and pseudoviruses are both replication-incompetent, meaning that multiple challenges
may be necessary in order to obtain sufficient selection.

Challenge dose must be

carefully titrated ahead of time, in order to be able to screen efficiently (without needing
to apply too many rounds of selection).
advantages and disadvantages.

Screening with live virus offers a mix of

The primary advantage is that live virus screening

allows you to probe all steps of the viral life cycle, as opposed to just the early entry
events that are mediated by the viral glycoprotein (which is what screening with a
pseudovirus does). Additionally, live viruses give you greater confidence that hits are
biologically meaningful, and not an artifact of the pseudovirus structure. One major
disadvantage to live virus screening, though, is the lack of control over multiplicity of
infection (MOI) during the screen. For example, if you apply virus to your library of 109
mutant cells at an MOI of 0.1 plaque-forming units (PFU) / cell initially, you can expect to
infect and kill ~ 10% of your cells. Then, if your virus replicates in 12 hours, with a burst
size of 1000 new virions per infected cell, that means that by the time your screening
plates have been allowed to sit in selection overnight, the MOI has changed from 0.1
PFU/cell to 1000 PFU/cell – quite a different challenge being encountered by the cells!
This idea of carefully controlling the MOI during the screen is important because
if the MOI is too high (such as the MOI of 1000 PFU/cell that can result after one round
of viral replication, as mentioned above) then you will lose intermediate phenotypes that
may be biologically meaningful and interesting. A gene whose disruption renders that
cell resistant to virus at a 10-fold higher level than wild-type cells, for example, could
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have a meaningful impact during viral infection, but this cell would succumb to viral
challenge at the MOI of 1000 PFU/cell, and would therefore not be pulled out as a hit in
such a screen.
On the other hand, if your MOI (or challenge concentration, in the case of toxins)
is too low, then the result is a decrease in the signal-to-noise ratio due to mutant cells
that survive challenge in a non-specific manner (that is to say, they never actually
encountered the selective agent). This is of particular concern due to the differences in
growth rate among the cells in the mutant library. There are many genes (often welldescribed oncogenes) that encode nuclear proteins whose loss results in a
hyperproliferative phenotype, and these genes have appeared as “hits” across multiple
screens. Although I have not formally tested this, I suspect that the reason we pull these
genes out as hits from unrelated screens is that their disruption increases the survival of
these mutant cells in a manner unrelated to the selective agent, owing merely to their
increased rate of replication (and resultant over-enrichment in the selected pool). This is
supported by the fact that I have seen a greater representation of such genes among the
hits from screens done with toxin (which lasted almost a month) than with screens done
with live virus (which last a week at most) because the longer screening duration would
allow for a greater over-representation of these hyperproliferative mutants.

For this

reason, it’s incredibly important to balance completeness of selection with minimizing the
duration of selection.
RECENT ADVANCES IN GENETIC SCREENING TECHNIQUES
The hunt for host-pathogen interactions going forward will be greatly aided by
many exciting developments in loss-of-function screening technology. In addition to the
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human HAP1 cell line, haploid cell lines have been generated from fish, mouse, monkey,
and rat embryonic stem cells (25–29). A fully haploid human cell line has also been
derived by genome editing using the clustered regularly interspaced short palindromic
repeats (CRISPR) RNA-guided endonuclease Cas9 to excise the fragment of
Chromosome 15 that was integrated onto Chromosome 19 and was preventing the
HAP1 cell line from being fully haploid (30). This updated cell line, termed eHAP, will
likely replace the HAP1 line in the generation of new mutagenesis libraries.
CRISPR technology has now also been applied to high-throughput functional
genomic screening. This DNA-editing technique was adapted from the type II CRISPR
bacterial adaptive immune system in which the endonuclease Cas9 is recruited to the
DNA of invading pathogens by two RNA components: a CRISPR RNA (crRNA) that
contains a DNA fragment complementary to the foreign target, and a trans-activating
CRISPR RNA (tracrRNA) which acts as a scaffold. The crRNA and tracrRNA can be
fused to form a single guide RNA (sgRNA), greatly simplifying the process of
synthesizing and delivering custom CRISPR/Cas9 machinery in order to disrupt a gene
of interest. The Cas9-induced cleavage triggers the cell’s double-strand break repair
response, leading either to indel mutations, or (if supplied) the introduction of a
sequence of interest. For a detailed technical review of CRISPR/Cas systems and their
utility for genome engineering, see reference (31).
Generation

of

sgRNA

libraries

providing

genome-wide

targeting

by

CRISPR/Cas9 has opened the door to a new method of high-throughput screening to
identify host factors required by pathogens. In one recent study, a CRISPR sgRNA
library was used to identify genes required for the induction of cell death by West Nile
virus (32).

In another, the Staphylococcus aureus toxin α-hemolysin was used to
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challenge a genome-wide CRISPR sgRNA library, and uncovered a role for
sphingomyelin synthase 1 (SGSM1), which regulates lipid raft formation (33). Lentiviral
vector delivery of the sgRNAs and the Cas9 endonuclease have been developed, and
are being optimized for efficient delivery (34).
THE NEXT GENERATION OF BIOCHEMICAL SCREENING TECHNIQUES
To identify potential cellular interacting partners of viruses and toxins, it is now
also possible to circumvent the requirement that proteins associate strongly enough with
the bait protein that they can be pulled down by the (T)AP/MS techniques. Martell and
colleagues introduced in 2012 a new genetically-encoded reporter molecule that can be
used for both electron microscopy as well as proximity labeling followed by MS to detect
nearby proteins (35, 36). The authors engineered a monomeric variant of ascorbate
peroxidase, which they have termed APEX, that is active in all cellular compartments
(including the cytosol), a major advantage over the horse radish peroxidase (HRP) tag
typically used. This APEX tag can oxidize biotin-phenol (in the presence of a hydrogen
peroxide catalyst) into phenoxyl radicals, and these short-lived radical species react with
electron-rich amino acids present in proteins that are fewer than 20 nm away. This
results in the biotin-labeling of endogenous proteins adjacent to the APEX-tagged
protein of interest, and these can be identified by streptavidin purification followed by
digestion and MS analysis. An improved version of this peroxidase, termed APEX2, was
recently obtained by yeast display evolution and exhibits increased activity, stability, and
sensitivity (37).
Another proximity-labeling approach developed in 2012 by Roux et al. is named
proximity-dependent biotin identification (BioID) and it employs a promiscuous mutant of
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the E. coli biotin ligase BirA fused to a bait protein of interest (38). As with the APEX
labeling technique, neighboring proteins that have been biotinylated within the cell can
be affinity purified and identified.

BioID has been used to better characterize the

constituents and architecture of the nuclear pore complex and to identify the interactome
of the Ewing sarcoma fusion oncoprotein EWS-Fli-1 (39, 40). This approach has also
been used to study host-pathogen interactions during bacterial and viral infection.
Mojica and colleagues fused the BioID BirA to SINC, a type III secreted effector from
Chlamydia psittaci, and showed that it targets the nuclear envelope of both infected and
neighboring cells (41). In 2015, Le Sage et al. used HIV-1 Gag protein fused to BioID to
identify 47 associated proteins that were biotinylated by the fusion protein when it was
transfected into Jurkat cells (42). Two of the putative host factors identified, DDX17 and
RPS6, were validated as interacting partners of Gag by co-immunoprecipitation
experiments. A substantially smaller biotin ligase, BioID2, was recently described to
have higher activity and to improve the function and localization of the resultant fusion
protein (43). These new proximity-labeling technologies represent exciting additions to
the screening toolbox.
NEW BUNYAVIRUS TECHNICAL RESOURCES
Recent advances in bunyavirus research have greatly expanded the options
available for generating bunyavirus reporter systems to enable high-throughput or
automated screening. Among orthobunyaviruses, a replication-competent recombinant
BUNV has been generated bearing a fluorescent or V5 tag on either Gc or L,
respectively (44, 45). In 2013, reverse genetics was described for Schmallenberg virus
(SBV) and in 2015 a BHK cell line was developed that constitutively expressed the SBV
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N protein and a minigenome system was described for Oropouche virus (46–48).
Efficient reverse genetics has also now been established for Akabane virus, further
expanding the options for bunyavirus screening approaches (49). For the phlebovirus
RVFV, there exists both a reverse genetics toolset as well as a BHK replicon cell line
expressing the S and L segments of the genome (50, 51). We and others have also
utilized pseudovirion systems, described in (52) and (53), in order to screen for host
factors required during entry of bunyaviruses. These pseudotyped virions can be used
at the BSL2 level and allow for the convenient use of either cell death or a geneticallyencoded reporter (e.g. luciferase or a fluorescent protein) to facilitate high-throughput,
cell-based screening approaches.
EXPANDING CELLULAR TARGETS
In addition to the screening techniques focused on genes and proteins, there has
been renewed interest in developing high-throughput approaches to identify metabolites
and lipids that are involved in viral infection.

Analysis with LC-MS can be used to

quantify changes in the metabolomic profile of infected cells relative to uninfected cells,
providing insight into pathogen alteration of host metabolism as well as yielding potential
therapeutic targets. This approach was used to quantify the levels of known metabolites
at different time points during infection with human cytomegalovirus (HCMV), herpes
simplex virus type-1 (HSV-1), and influenza A (IAV), demonstrating each virus’s ability to
differentially remodel the host’s metabolism during infection (54–56). In the case of
HCMV and IAV, pharmacological inhibition of fatty acid biosynthesis was shown to
effectively restrict viral replication, demonstrating the power of such screens to inform
the development (or re-purposing) of therapeutics.
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In 2013, Morita and colleagues

tested a library of bioactive lipids for an effect on IAV replication, and observed potent
inhibition with the lipid mediator protectin D1 (PD1) (57). Treatment with PD1 was able
to protect against influenza in a mouse model, even if it was not supplied until severe
disease had developed.
Another important aspect of host-pathogen dynamics that could be examined is
that of interactions between RNA and proteins during viral infection. Yeast three-hybrid
screening provides a powerful tool for identifying proteins that bind to a specific RNA
sequence. This technique, first described by SenGupta and colleagues (58), detects
RNA-protein interactions by utilizing two hybrid proteins whose proximity activates a
reporter gene when both proteins bind to a hybrid RNA molecule. Yeast three-hybrid
screening was used to identify human ribosomal proteins that bind to the 3' untranslated
region of hepatitis C virus (HCV) using a human cDNA library as prey and the viral RNA
sequence as bait (59). Covalent UV crosslinking during infection could also be used to
capture and characterize the RNA-protein interactome in a manner similar to the
technique described by Castello et al. in 2012 (60).
COMMON THEMES OF VIRUS AND TOXIN ENTRY
Haploid genetic screening, as well as most of the other screening modalities
discussed in this thesis, can be used to probe for host factors utilized by a variety of
pathogens. Although our lab historically has studied interactions between viruses and
host cells, I decided to do a screen using C. difficile’s TcdB toxin because early entry
events during virus and toxin invasion of host cells share many common themes.
The initial attachment of the bunyavirus glycoprotein to a cell-surface receptor,
the internalization of the virion as a result of this interaction, and the entry of the virion
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into the endocytic pathway of the cell are mechanistically similar to the binding and
internalization of many bacterial toxins.

Bunyavirus glycoproteins likewise mediate

fusion of viral and cellular membranes within acidified endosomes, in a manner that
echoes the pore formation activity of TcdB toxin.

Indeed, many virus entry studies

employ virus-like particles (VLPs), often containing only the glycoprotein, to examine
early entry events. This highlights the parallels between glycoprotein-driven virus entry
and entry of toxins.
Studies of virus entry and toxin entry can inform each other on both the host as
well as the pathogen side. Characterization of the cellular endocytic machinery, for
example, informs (and is informed by) our understanding of host factors required by the
viruses and toxins that hitchhike within the endolysosomal pathway as they enter the
cell. Many technical tools used for virus entry assays also have the potential to be
applied to toxin entry studies. For example, the fusion of β-lactamase protein to HIV Vpu
provides an excellent tool to assay fusion of the virus at the plasma membrane. In this
assay, the cell is loaded with a fluorescent dye cleavable by the β-lactamase protein,
and cleavage of the dye therefore indicates that the virion contents have gained access
to the cytosol (aka fusion has occurred). I have adapted this assay in our lab to look at
fusion of bunyavirus pseudovirions from within endosomes, and it could be nicely
applied to study TcdB toxin pore formation. For this purpose, the β-lactamase protein
would need to be fused to the N-terminus of the toxin, as it is the glucosyltransferase
domain that is translocated through the endosomal membrane and then cleaved off into
the cytosol.
Other classical virus entry assays could be useful when looking at entry of toxins,
such as acid-bypass experiments in which the pH is lowered in order to drive fusion at
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the plasma membrane and bypass the requirement for receptor-mediated endocytosis.
Likewise, many of the reagents that we learn about when studying virus entry have also
been used to look at toxin entry, especially those that inhibit endocytosis pathways.
These tools include lysosomotropic agents; inhibitors of clathrin-mediated endocytosis,
dynamin, macropinocytosis, and caveolae; expression of dominant-negative versions of
cellular proteins such as Rab and Rho GTPases; and cytoskeletal drugs targeting actin
and microtubules; as well as many others. Because viruses and toxins rely on much of
the same cellular machinery to enter the host cell, studies looking at the early entry
events of viruses and toxins are really not so philosophically disparate at all, especially
in their roles as probes to uncover novel elements of these fundamental cell biology
processes.
FUTURE PERSPECTIVES
The screens presented here demonstrate the utility of unbiased forward genetic
screening to identify host cellular factors used by the bunyavirus Rift Valley fever virus
(RVFV) and the large clostridial glucosylating toxin TcdB. The pathways hit by these
screens include heparan sulfate biosynthesis, which is required for attachment of RVFV
at the cell surface, and endosomal transport protein complexes, which play a role in the
cytotoxicity of TcdB.

Many important questions remain about the exact role of the

WASH complex and the CCC complex in TcdB entry, as well as the possible
significance of other hits from the TcdB screen such as SNX17, HOOK2, and RAB10.
These factors all have demonstrated roles in the regulation of endosomal transport, but it
is unclear how their known functions may (or may not) impact TcdB entry and trafficking.
Toxin resistance phenotypes of mutations in these genes may be due to indirect effects,
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such as loss of expression of a receptor at the cell surface. Since TcdB has been shown
to use multiple receptors in a cell-type-dependent manner, it is possible that there exists
an as-yet-unidentified proteinaceous receptor that plays a role in its entry into HAP1
cells, and whose expression (e.g. via recycling) is dependent upon the proteins and
complexes that were hit in this screen. Preliminary immunofluorescence imaging studies
suggest that there is a toxin trafficking defect in WASH-deficient cells, and that toxin may
remain associated with EEA1-positive endosomes in the absense of a functional WASH
complex, but this remains to be conclusively demonstrated. One intriguing possibility is
that the WASH complex is required for pore formation of TcdB due to a role in lysosomal
maturation, which has been observed in amoeba cells (61).

Because an acidic pH

triggers the conformational change in the toxin that allows for translocation of the
glucosyltransferase and cysteine protease domains, a defect in endosomal acidification
is a likely explanation for the cytotoxicity defect observed in WASH-deficient cells.
Introduction of a fluorescent tag to track the subcellular localization of the
glucosyltransferase domain of the toxin would be a logical next step in this study, and I
am very interested in performing these and other follow-up experiments to see where
this project will lead.
The haploid genetic screening techniques used for the studies presented in this
thesis, as well as the other screening approaches discussed, are powerful tools for the
investigation of host-pathogen interactions. As we grapple with emerging viral diseases
and enter the age of antibiotic-resistance, it is becoming increasingly important to
identify factors required by viruses and toxins as they invade the host cell. Dramatic
innovations in recent years of high-throughput screening techniques promise to push
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forward our understanding of how pathogens interact with their host cells, and will help
us to develop targeted therapeutics.
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Portions of the text in this chapter were modified from:
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